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SERUM PROLACTIN LEVELS  IN PATIENTS WITH  RECENTLY DIAGNOSED 
RHEUMATOID ARTHRITIS. 
ABSTRACT 
OBJECTIVES: The role of  Prolactin in autoimmune diseases & use of anti Prolactin drugs  
in disease remission has been described & investigated in several studies. The role of anti- 
prolactin drugs  in remission of disease activity have been investigated.  The present study 
was carried out to correlate serum Prolactin levels with disease severity in recently diagnosed 
Rheumatoid Arthritis patients. 
MATERIALS and METHODS: A case-control study was carried out in 55 recently 
diagnosed untreated Rheumatoid factor positive & RF negative  Rheumatoid Arthritis 
patients and 27 age & sex matched apparently healthy individuals. The diagnosis of RA was 
made using  ACR criteria 2010.  Serum Prolactin(ELISA) ,serum Anti CCP( ELISA), RF 
(Latex agglutination method) , TSH(ELISA),ESR( conventional Westergrens method),Serum 
urea & creatinine were assayed.  Disease severity was assessed by DAS(28) formula. 
Statistical evaluation was done  by independent t-test,ANOVA, Pearson correlation co-
efficient   
RESULTS: Serum Prolactin levels in RA patients was significantly higher (33.53±17.9 
ng/mL) compoared to controls (14.4±5.9) with p value of ˂  0.001  . A fair correlation was 
found between disease activity and serum Prolactin levels ( r = 0.345 ; p = 0.01 ).  
CONCLUSION : Elevated levels of serum prolactin indicates the immunomodulatory role 
of PRL and its relationship to diseases activity. Use of Anti Prolactin drugs may be of use in  
patients with hyperprolactinemia. 
Key words:  Prolactin , autoimmune disease , rheumatoid arthritis 
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INTRODUCTION 
Rheumatoid Arthritis is an autoimmune disease. Affects 1 to 2% of general 
population. As any other autoimmune disease it is commom in women .The male to 
female sex ratio is 2:11. This female gender bias suggest ; female hormones play a 
role in pathogenesis. The hormones Estrogen and Prolactin are related. The pituitary 
expression of Prolactin is under the control of estradiol2. 
Role of Pituitary hormones in immune system modulation has been 
suggested right from 1930s.Prolactin one of the anterior pituitary hormones plays a 
major role in immune regulation .Many clinical ,invitro, invivo animal and clinical 
studies suggests Prolactin exhibits immunoregulatory properties2.At times of stress 
Prolactin is needed to balance the effects of glucocorticoids and other inflammatory 
mediators3. Prolactin upregulates the expression of Th1 cytokines. Th1 cytokines are 
involved in autoimmune diseases 4,5. 
Clinical datas suggest that altered Prolactin concentration in serum 
exacerbates certain Autoimmune diseases but a clear causal relationship is still 
lacking. Certain case reports show that administration of Bromocryptine , 
cabergoline in Rheumatoid Arthritis  patients with elevated serum Prolactin cause 
disease remission6. But these evidences were not consistent . Hence the present 
study was carried out to determine the status of serum Prolactin in patients with 
recently diagnosed Rheumatoid arthritis.  
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REVIEW OF LITERATURE 
RHEUMATOID ARTHRITIS  
Rheumatoid arthritis , the most common chronic inflammatory disease 
affecting synovial  lining , bursae & tendon sheath is a prototype disease entity for 
defining the molecular & pathological  basis of chronic inflammatory syndrome. 
The term rheumatoid arthritis was coined by Garrod.7 
EPIDEMIOLOGY: 
       0.5 to 1 % of the general population is affected. The prevalence is constant 
across the globe irrespective of race and geographical location1.Onset is most 
frequent between  4th and 5th decades of life. 80% of individuals develop the disease 
between 35 and 50 years of age. Incidence in 60 year old women is 6 times greater 
when compared with 18 to 29 year old women7. The female to male ratio is  
2:1 to 3:1. 
RISK FACTORS: 
1. AGE:  Immune senescence occurs in old age. Immune senescence is also 
considered as a possibility of Autoimmune diseases . Immunesenesence is 
characterized at molecular and cellular level by massive expansions of lymphocyte 
clone, telomere erosion of leukocytes , corresponding contraction of nai ̈ve T & B 
cell repertoires. All these represents an extensive proliferative history. 
Derangements in pathways integral to antigen responsiveness and immune 
regulation occurs in old age. These factors combine to  
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• Increase susceptibility to foreign pathogens. 
• Auguments reactivity to self antigens. 
• Generate a repertoire of lymphocytes defective in tumor surveillance.        
Hence immune senescence in old age could be considered a risk factor in 
development of Autoimmune diseases.7 
2.  GENES IMPLICATED IN RHEUMATOID ARTHRITIS: 1 
     About 35 genes are implicated in the pathogenesis of RA identified by 
genome wide screen  .The most common genes are 
• Genes of MHC Class II  
• PTPN 22- Protein tyrosine phosphatase 22( a phosphatase that regulates 
phosphorylation status of many kinases responsible for T - cell activation) 
• Cytokine promoter polymorphism 
• Signal transduction gene polymorphism 
• Population specific genes eg: PADI 4 in Japanese people . 
3.   HLA –DR:1 
• HLA –DR is present in 70% of Rheumatoid arthritis patients. 
• The 3rd hypervariable region of DR-β chain from aminoacid 70- 74 
(QKRAA,Glutamine-leucine-arginine-alanine - alanine)  comprises 
the  disease susceptibile region. 
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• This susceptible epitope is associated with HLA –DR4β subtypes like 
DRB*0401,DRB*0404,DRB*0101,DRB*1402. 
• These susceptible epitopes has a role in shaping the T- cell repertoire 
in thymus. 
• They alter the intracellular HLA trafficking and antigen loading. 
4.  MICROCHIMERISM : 1 
                Maternal cells expressing the susceptibile epitope (QKRAA) can persist in 
a child , these non inherited maternal antigens confers increased risk of disease in 
these children. 
5. SEX: 1 
            Autoantibody producing B cells exposed to estradiol are more resistant to 
apoptosis. It might escape peripheral tolerance. Hence autoimmune diseases are 
more common in women.    
6.  HORMONAL FACTORS: 1 
         The first 3 months of Postpartum period, the disease activity is more in a 
Rheumatoid Arthritis patient .This is attributed to the hormonal changes during 
pregnancy especially Prolactin. Decreased androgen and increased estrogen status in 
males is associated with Rheumatoid arthritis. Extended periods of breast feeding is 
associated with increased risk of Rheumatoid Arthritis. This again is associated with 
elevated serum Prolactin. 
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7.  SMOKING:1 
            Smoking 25 cigarettes per day for >20 years confers a 15 fold increased  risk 
of Rheumatoid arthritis in subjects who carry disease associated HLA –DRB1 
allelles. 
8.  URBAN DWELLING: Urban dwelling provokes Rheumatoid arthritis in a 
genetically prone individual.1 
9.  PATHOGENS:7 
• Exposure of mucosal surfaces such as lungs, periodontium, gut to infectious 
antigens may induce RA in susceptible individuals. 
• Antibodies to nuclear antigens of Epstein Barr virus is seen in Rheumatoid 
arthritis patients. 
• Porphyromonas gingivalis – causative organism in periodonitis is capable of 
generating citrullinated proteins. 
• Filamentous bacteria in gut induce T cells of lamina propria to generate IL 
17 that induce inflammatory arthritis.  
AUTO ANTIGENS IN RHEUMATOID ARTHRITIS : 7 
Rheumatoid arthritis is an autoimmune disease, antibodies are produced 
against self antigens. Some of the self antigens implicated in RA are as follows 
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Table I Proven Antigens in RA & the available assay: -  
Antigen Molecular specificity Assay to identify 
IgG Human Fc fragment of IgG Rheumatoid factor 
Cyclic Peptides Citrullinated peptides Anti – CCP Ab 
Vimentin Citrullinated  Vimentin 
MCV assay 
Mutant citrullinated 
Vimentin 
 
Table II Unproven Antigens in RA ( under research) : 
Antigen Cell type Molecular specificity 
Glucose 6 phosphate 
isomerase 
Both B& T Multiple epitope 
Enolase B CEP-1  
Fibrin B Αlpha & β chain epitopes 
Fibrinogen B &T Multiple epitopes 
Collagen II B& T Multiple epitopes 
hn RNPA 2 B&T Multiple epitopes 
Aggrecan B&T Multiple epitopes 
Hcgp-39 B&T Multiple epitopes 
 
 
 
 
7 
 
PATHOGENESIS: 
Although it is a well known fact that Autoimmunity plays a pivotal role in 
pathogenesis of RA ,pathogens do have a role in Pathogenesis of RA. Predominance 
of CD4+ T- cells in circulation and presence of IL2 in synovial fluid and blood of 
these patients indicate that Rheumatoid arthritis is a immunologically mediated 
event7.No single specific pathogen for RA is unlikely .Some of the infectious agents 
found to be associated with RA are Mycoplasma , Parvo virus B19,Retrovirus 
,enteric bacteria,mycobacteria,EBV, Bacterial cell wall.The mechanisms  through 
which these agents cause RA are direct injury , molecular mimicry and activation of 
TLR.  
TOLL LIKE RECEPTORS(TLR) and RHEUMATOID ARTHRITIS: 1 
• TLR are a part of innate immunity .These receptors are expressed by sentinel 
cells and they provide the first line of defence.    
• These receptors recognize constitutively  preserved structures; molecular 
patterns like peptidoglycans , dsRNA  , lipopolysaccharide ,DNA in 
infectious agents  like bacteria and virus. Permits rapid release of 
inflammatory mediators and activates Antigen Presenting Cells and thereby 
adaptive immunity is activated. 
• TLR-3 recognizes double stranded RNA 
• TLR-7 recognizes single stranded RNA 
• TLR-9 recognizes double stranded DNA 
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• TLR-2 recognizes peptidoglycan 
• B lymphocytes bear TLR-7 and 9 
• Dendritic cells bear either TLR-3 or both TLR-7and TLR-9. 
• Fibroblast carry TLR -3 
• TLR are expressed by Rheumatoid synovial tissue & cultured FLS( 
Fibroblast like synoviocytes) 
• Repeated engagement of these TLRs  would initiate RA in a  genetically 
susceptible individual .Repeated activation of TLR could break immune 
tolerance and permits autoimmune response to occur in a  genetically 
susceptible individual 
NORMAL IMMUNE BALANCE & SELF TOLERANCE 
RA is an autoimmune disease. Understanding of normal immune balance and 
self tolerance mechanisms would help us to understand the pathogenesis of 
autoimmune diseases. 
IMMUNE BALANCE 
Cytokines released from T helper lymphocytes balances cell mediated and 
humoral immunity.Cell mediated immunity is regulated by cytokines –IL-2 ,IFN-γ 
which are released by Th1 cells. The cytokines IL-4,IL-5,IL-10 released by Th2 
regulates humoral immunity 8,9.IL-12,INFγ inhibits Th2 response,IL-10 and IL-4 
inhibits Th1 response .Thus both Th1 and Th2 responses are mutually inhibitory10. 
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Human leukocyte antigen complex 11 
The HLA complex helps the immune system to distinguish between self 
antigens and  from proteins made by foreign invaders such as viruses and bacteria. 
More than 200 genes located closely on chromosome 6 comprises the MHC 
complex. It is categorized as class I, II,III.HLA –A, HLA-B,HLA-C are the 3 main 
classes of MHC class I; whose products are present on the surface of  almost all 
nucleated cells .The 6 main MHC class II genes in humans: HLA-DPA1, HLA-
DPB1, HLA-DQA1, HLA-DQB1,HLA-DRA, and HLA-DRB1.  Each person's 
immune system react to a wide range of foreign invaders because of possible 
variations in HLA genes. HLA  is inherited as a set of 3 haplotypes.We have a 25% 
chance of inheriting same HLA as any one of our siblings. 25% chance of not 
inheriting the same haplotype. 50% chance of sharing one haplotype with our 
siblings. There is 1 in 4 chance of being an identical match withour siblings 
IMMUNE TOLERANCE 11 
Deletion, anergy , suppression are the three common mechanisms taking 
place in our body which protects us from  autoimmunity.20The immune tolerance is 
classified as central and peripheral based on the lymphoid organ where it takes 
place. 
         Deletion is the process occurring in central tolerance. Anergy and 
suppression are the processes occurring in peripheral tolerance. 
Central tolerance is the process of destruction of self reactive T- Cells in 
Thymus. Progenitor T cells migrate to Thymus for maturation during 8th to 9th week 
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of gestation in humans .A T- Lymphocyte express 10^5 receptors exhibiting 10^10 
different antigen specificities.In thymus positive and negative selection of T cells 
occur. Positive selection is the process of  allowing the maturation of T cells with 
low affinity receptors for self antigens presented by  MHC molecules. Negative 
selection is the process  where elimination of T cells which reacts strongly with self 
MHC molecules occur.          
 In thymic cortex destruction of T-cells that reacts with self antigens 
presented by MHC II in the presence of co-stimulatory molecules occurs. In thymic 
medulla destruction of T- cells that reacts with Antigens presented by MHC I in the 
absence of co-stimulatory molecules and MHC II occurs .The apoptosis takes place 
by a controlled interaction between Fas and Fas ligand.20 
            Anergy is  induced  by insufficient co-stimulation thereby causing 
unresponsiveness in an autoreactive cell clone. It is a process of peripheral tolerance.  
Clonal suppression is another peripheral tolerance mechanism where 
cytokines released by CD4+, CD25+ -Tregulatory cells ,CD8+ suppressor cells 
quenches the anti- self responses.  
 B Lymphocytes matures  in bone marrow. The specificity of B lymphocyte 
towards an antigen is created by random rearrangement of a series of gene segments 
that encodes the antibody molecule. A single naïve B cell is estimated to exhibit 
10^10 different antigen specificities.  This diversity is restricted by the process of 
negative selection i.e. B cells that reacts with self antigens are eliminated 
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               These are the mechanisms of immune tolerance that prevent or subsides the 
autoimmune response.  
AUTOIMMUNITY11 
The inappropriate response of immune system towards self components is 
Autoimmunity. The reason is 
All self reactive lymphocytes are  not deleted during T-cell and B- cell 
maturation . 
Normal healthy individuals posses self reactive cells in circulation and it is 
suppressed by clonal suppression; defect in clonal suppression leads to activation of 
these self reactive clones.  
RISK FACTORS FOR AUTOIMMUNE DISEASE   :              
Autoimmunity is a natural phenomenon. Self reactive antibodies and 
autoimmune cells are present in all normal individuals. The combination of genetic 
predisposition and  environmental factors contributes to development of disease, 
where the participation of genetic predisposition is 1/3rd and the remaining 2/3rd is 
by environmental factors.HLA haplotype, is the best available predictor of 
developing an autoimmune disease. The likelihood of developing similar 
autoantibodies is related directly to sharing HLA haplotypes with family members 
and the probability is even greater if two haplotypes rather than one are shared. 
Genes outside the MHC also contribute to the risk for developing autoimmune 
disease . 
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Environmental agents like diet , hormones , toxins , infectious substance and 
drugs amplify autoimmunity in genetically susceptible individuals. These agents 
break tolerance in genetically susceptible individuals, and increases the risk of 
developing autoimmune diseases. 
HORMONES 
Steroid hormones , estrogens and androgens are known to influence antibody 
production and immune cell proliferation .Thus hormones can amplify or inhibit the 
immune response. Women produce elevated antibody response compared to men, 
while men often develop more severe inflammation.  
DIET & AUTOIMMUNE DISEASES 
Food additives & pesticides may contribute to autoimmunity . Certain 
evidences are Iodine inducing antibody formation against thyroglobulin in 
autoimmune thyroiditis. Hypersensitivity to gluten in diet induces antibody 
formation against transglutaminase , actin and calreticulin.   
DRUGS & TOXINS  
             Drugs induce autoimmune diseases. Example- Procainamide, Penicillamine 
result in Lupus like disorders. These symptoms ameliorate with drug withdrawal. 
INFECTION 
There are evidences to show that infections are associated with autoimmune 
diseases. 
• Coxsackievirus  and CMV in TypeII Diabetes mellitus and myocarditis. 
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• Measles and EBV in Multiple Sclerosis . 
• Mycobacteria and EBV with Rheumatoid arthritis. 
Association of multiple diverse microorganisms with a single autoimmune 
disease suggest that a common mechanism induce autoimmune disease in 
genetically prone individuals, which can be 
• Direct viral damage 
• Release of Cryptic self peptides  
• Antigenic spread 
• Molecular mimicry (Microbial Ag closely resembles self antigens) 
• Adjuvant effect (specific activation of innate immune response by microbes 
eg- vaccine administration) 
• Bystander activation ( non specific immune response stimulated by infection 
results in activation of autoimmune response)  
 A number of animal models of autoimmune diseases had been studied using 
the above said mechanisms. Examples for adjuvant effect are 
o Rheumatoid arthritis in mice with collagen  
o Multiple sclerosis with myelin basic protein 
o Myocarditis with cardiac myosin 
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CYTOKINE IMBALANCE 
 A inflamed tissue is subjected to cytokines released by B cells, activated 
cells like endothelial cells, fibroblast , synoviocytes . To downregulate the immune 
response in that tissue , it utilizes the cytokines released by T cells and macrophages 
A balance exists between these pro-inflammatory and anti-inflammatory cytokines. 
Autoimmune disease of a organ occurs when this balance gets disrupted. 
DYSREGULATED INTRACELLULAR SIGNAL TRANSDUCTION  
Inappropriate activation of naive T cells and retention of T cells occurs in 
deficiency of cytotoxic T–Lymphocyte antigen CTLA-4.21 Altered amounts of 
STAT-3 and deregulated signaling by NFKB are seen in certain autoimmune 
disases.11. 
NEO ANTIGEN FORMATION 
Epitope conformation of a endogenous molecule is altered when a hapten is 
conjugated with it. The haptens are usually metals , toxic substance or chemical 
conjugates .This altered epitope in that  endogenous molecule may provoke 
autoimmunity.  
AUTOIMMUNE DISEASE 
Normal minimal amount of autoantibodies present in circulation helps us in 
clearing cellular debris associated with inflammation. Any alteration in mechanisms 
that regulate inflammation or immune responses by environment or genes makes this 
autoimmune response exaggerate to autoimmune disease. Autoimmune diseases are 
classified as organ specific and systemic, based on whether autoimmune response is 
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directed against a particular tissue or widespread . Autoimmune diseases are 
characterized by presence of autoantibodies , inflammatory cells and cytokines. 
AUTO ANTIBODIES IN AUTOIMMUNE DISEASE 
1. Activates the complement system and cause cell lysis eg: hemolytic anemia 
2. Binds with cell surface receptors and alters the function of that receptor 
eg:antibodies against thyrotropin receptors in Graves disease, antibodies 
against Ach in Myasthenia gravis 
3. Deposition of antibody – complement complex over joints and vessels 
causing tissue damage eg: Lupus, Rheumatoid arthritis , inflammatory heart 
disease. 
IMMUNE CELLS IN AUTOIMMUNITY & DISEASE 
1. The cells involved are macrophages, neutrophils, CD4+ T Helper cells , 
CD8+ cytotoxic T cells, Natural killer cells , mast cells , dendritic cells. 
2. Tissue macrophages and monocytes acts as antigen presenting cells to 
initiate an autoimmune response. 
3. Macrophages destroys cells through antibody dependent cell mediated 
cytotoxicity or by secreting cytokines- TNF , IL-1,which in turn recruits 
other inflammatory cells like neutrophils and T-cells. 
4.  Macrophage and neutrophils damage tissues by releasing nitric oxide or 
hydrogen per oxide. 
5. IL-4 released by Th1 acts on B cell to produce immunoglobulins.12    
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ROLE OF CD4+ T CELL: 7  CD4+ T cells on exposure to a self Ag 
                        A.  CD4+ T Cell differentiates into TH1 like effector cells 
 
                                           release of INF-γ from TH1 cells 
 
INF-γ stimulates macrophages to release proinflamatory cytokines IL-1 & TNF 
 
INFLAMMATION 
B.T-Cells release cytokines that promote B Cell proliferation and 
differentiation 
                                       
Production of immunoglobulins(polyclonal activation)   
occur  against self antigens – RF, ACPA 
 
                                Formation of immune complex 
 
Complement activation cause  Tissue damage by type III hypersensitivity reaction  
17 
 
 
Figure 1- immune cells and autoimmune mechanisms 
 
Courtesy: V.Kumar et al .1989 Annu Rev. Immunol 7:657 
This figure explains various cell involvement in an autoimmune response 
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PROGRESSIVE NATURE OF AUTOIMMUNE DISEASE  
The chronic cell and tissue injury leads to continuous release of self antigens 
.When the condition is favourable for antigen presentation and co-stimulation ; 
epitope spread occurs. Further increased activation of lymphocytes that recognizes 
self antigens  and their expansion leads to chronicity of Autoimmune disease. 13 
AUTOIMMUNITY IN RA:1 
Autoimmunity plays a major role in RA and autoimmune response precedes 
the onset of disease by many years. Autoimmune response can be directed against 
articular antigens and Non – articular systemic antigens .The articular antigens are 
TypeII collagen in cartilage and glycoprotein 39 in cartilage. The non-articular 
antigens are Glucose-6-phosphate isomerase, heat shock proteins , heavy chain 
binding proteins,hnRNPA2 . 
Type II collagen 
Antibodies against type II collagen in RA is capable of generating C5a when 
these antibodies bind with type II collagen in cartilage , this can amplify the 
inflammatory response and it is not an initiating event.   
Glycoprotein 39 
Peptides of Glycoprotein 39 from the cartilage binds with HLA DR*0401 
and stimulates proliferation of T-lymphocytes. Gp39 has been detected  in a small 
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group of patients and are found to be highly specific for RA. Presence of Gp39 is 
associated with less aggressive disease. 
Heterogenous nuclear Ribonucleoprotein-A2(hn RNPA2) 
          hn RNPA2 or RA 33 occurs in one third of RA patients and other autoimmune 
diseases.RA-33 positive patients tend to have a less severe disease.  
An algorithm including anti RA33, RF, Anti CCP had been used in patients 
with early synovitis to predict the progression to erosive RA.1 
The major autoantibodies involved in RA are Rheumatoid Factor( RF) and 
Anti Citrullinated Protein Antibody( ACPA) and they are explained in detail. 
Modification in structure of a self antigen and generation of neoepitope are 
the two proved mechanisms of initiation and provocation of Autoimmune response 
in Rheumatoid Arthritis. 
CHANGE IN STRUCTURE OF THE ANTIGEN:1 
Non antigenic soluble monomeric  IgG form immune complex with Fc 
fragment of IgG thus the structure of Ig gets altered leading to generation of 
Rheumatoid factor 
RHEUMATOID FACTOR :7 
• Presence of Rheumatoid Factor is a cardinal feature of RA.The antibody that 
binds with Fc fragment of heavy chain of IgG is the Rheumatoid factor 
.Presence of RF is an evidence for autoimmunity in Rheumatoid arthritis. 
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• Presence of Rheumatoid factor  precedes disease onset by many years. 
seroconversion occurs during the 1st year of disease activity. 
• These antibodies activate the classic complement pathway. Large quantities 
of IgG RF produced by synovial tissues form complexes with one and 
another and gets deposited over the synovial tissues, facilitating complement 
fixation and release of chemokines. 
• The proof of involvement of RF in RA is that RF levels increases with 
clinical relapse and decreases with remission of disease activity. Some 
patients initially though seronegative to RF subsequently convert to 
seropositive typically during the first year of disease activity. 
• Rf directed against IgG and IgM are abundant in patients with RA .Other 
than IgG RF; IgM RF , IgERF & IgARF are also present in RA patients. 
• 75% of patients with RA are seropositive with standard agglutination assays 
whereas 90% are seropositive positive when assayed for IgM RF ELISA   
• The Standard agglutination tests primarily detect IgM RF , but the 
seronegative patients usually have IgA RF. 
• Immune complex formed by IgE RF cause degranulation of mast cells. 
• Rheumatoid factor present in 5% of normal individuals are considered to be 
germline derived and have low affinity for Fc fragment of heavychain of  
IgG. 
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• Rheumatoid factor seen in RA patients are formed due to gene rearrangement 
and somatic mutations of germline genes. 
• Predictive value of Rheumatoid factor in diagnosis of rheumatoid arthritis is 
poor , only 1/3 rd of RF positive individuals had Rheumatoid arthritis. 
• It is also positive in other autoimmune diseases like SLE, Sjogrens syndrome 
, Sarcoidosis , Interstitial pulmonary fibrosis and other diseases like  chronic 
liver disease, tuberculosis, malaria, syphilis, hepatitis B etc.   
• IgA RF is a better indicator of T-Cell dependent affinity matured antibodies 
directed to particular Fc- gamma epitopes relevant to RA  
• Combined detection of IgM&IgA RF is a strong indicator of RA 14 
GENERATION OF NEO- ANTIGENS: 
Citrullination of proteins is a post translational modification. Citrullination 
occurs by Peptidyl Arginine Deiminase enzyme that converts arginine to citrulline 
by removal of the imine group. 
 ANTI CITRULLINATED PROTEIN ANTIBODIES:  
ACPA are immunoglobulins that bind with citrullinated proteins and are 
produced by patients with RA. Citrulline is a derived AA formed from 
posttranslational modification of Arginine by PADI 
  It is an important surrogate marker for diagnosis & prognosis of RA because 
they are  
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• As sensitive & more specific than IgM RF in both early & fully established 
RA. 
• Predicts the eventual development into RA when found in undifferentiated 
arthritis 
• Marker of erosive disease in RA 
• Detected in healthy individuals years before disease onset. 
Anti perinuclear factor was described in 1964 as a marker for RA . Anti 
keratin antibodies was described as a marker in 1974. Post translationaly modified 
vimentin – Sa antibody in 1994.  It was discovered in 1998 that all these antibodies 
target citrullinated proteins . Citrullinated peptides fit better in the HLA DR4 Ag 
binding groove than the corresponding non- citrulline containing peptides . Different 
linear citrullinated peptides are seen in serum of different patients , suggesting a 
polyclonal response. The flanking regions around the citrulline are also important , 
hence all sera will not react with every peptide 14.   
•    The proteins that undergo citrullination are usually vimentin, fibrinogen, 
fibronectin, EBV derived peptides. 
• Citrullination of proteins is mediated by the enzyme PADI- Peptidyl 
Arginine     Deiminase Ec 3.5.3.15 15; there are 4 isoforms and the common 
ones are PADI2 and PADI4. 
• The usual changes are conversion of Glycine to Arginine in the primary 
sequence and citrullination of these newly formed arginine or anyother 
arginine residues. 
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• Citrullination as such increases T Cell responses to arthritogenic antigens 
• Antibodies against citrullinated proteins activates both the classical and 
alternative pathway. 
• IgE ACPA sensitizes basophils and cause mast cell degranulation. 
• Inheritance of specific HLA – DRB1 allelle favour T and B cell immune 
response to host derivatized non epitope peptide antigen. 
•  The induction of PADI expression and citrullination of peptides are not 
specific for RA, this can also occur in other inflammatory settings.16 
• Detection of ACPA is 90% specific . Positive in 80 to 90% of patients. 
• These antibodies seen in circulation are synthesized by synovial B cells. 
They appear long before the clinical disease. 
11. Mechanism of ACPA formation is shown in figure 2. 
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• INTERPRETATION of Anti CCP: 
            < 20U/mL                      NEGATIVE 
20 to 39.9U/mL             WEAK POSITIVE 
40 to 59.9 U/mL            POSITIVE 
≥60U/mL                       STRONG POSITIVE 17. 
• Anti CCP is not useful to predict the future development of disease since 
1.5% of normal individuals possessing this antibody did not develop the 
disease. 
• Anti CCP positive individuals are more prone for aggressive and erosive 
disease.18 
• Anti CCP positivity is also a independent risk factor for ischemic heart 
disease incidence in RA patients.7 
ENVIRONMENTAL FACTORS ASSOCIATED WITH RHEUMATOID 
ARTHRITIS: 
Smoking Tobacco and silica exposure are the two agents associated with 
Rheumatoid Arthritis. 
TISSUE DAMAGE IN RHEUMATOID ARTHRITIS: 
The first phase is production of activated T and B lymphocytes by 
neoantigen ie citrullinated protein . Peptidyl Arginine Deiminase enzyme is released 
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by apoptotic granulocytes and monocytes. The activated T cell in turn stimulates 
macrophages, synovial fibroblast , endothelial cell, mast cell , osteoclast. These 
activated cells release cytokines like TNF, IL-1 , IFN-γ, MMP , Osteopontin leading 
to synovitis , pannus formation , bone erosion , cartilage destruction. 
Direct cell injury also occurs by rheumatoid factor activation of Classical 
complement pathway.  
Less effective clearance of antigen – antibody complex occurs in RA patients 
causing further damage. 
Spread of arthritis occurs by migration of fibroblast like synovial cells. 
RF vs Anti CCP 
RF is more sensitive than Anti CCP but not specific.1st generation ELISA for 
anti CCP used several fillagrin epitopes, had a sensitivity of only 65-70%. 
Cyclisation improved the sensitivity, hence 2nd generation ELISA used cyclic 
epitopes that mimicked true conformational epitope. 3rd generation ELISA and 
Chemiluminescence have increased sensitivity with similar specificity 14,15 
BIOMARKERS IN RHEUMATOID ARTHRITIS 
Autoantibodies: IgM RF, IgA RF , ACPA 
Acute Phase Response markers : ESR,CRP, IL-6 
Synovial Vascularity: VEGF 
Cartilage Metabolites: Matrix metalloproteinase MMP1&3, COMP- Cartilage 
Oligomeric Protein, Aggrecan cleavage fragments , c- terminal collagen II  
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Bone metabolites: Pyridinoline cross links , Carboxy terminal collagen I 
telopeptides.  
MARKERS THAT ANTEDATE  DISEASE : These auto –antibodies are present 
in serum long before onset of disease activity 
1. IgM RF 
2. ACPA- Anti citrullinated vimentin  
                         Anti citrullinated α enolase 
                          Anti citrullinated fibrin 
PREDICTORS OF RADIOGRAPHIC PROGRESSION: Concentration of these 
antibodies correlate with joint damage 
1. IgM RF 
2. ACPA 
3. VEGF 
4. MMP 1&3 
5. C terminal collagen II in urine 
PREDICTORS OF JOINT DAMAGE IN EARLY RHEUMATOID 
ARTHRITIS: 
1. COMP- Cartilage Oligomeric Protein. 
2.  C-terminal collagen I telopeptides. 
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SEEN IN EXTRA-ARTICULAR DISEASE: 
1. IgM RF – severe extra articular disease. 
2. IgA RF 
MARKERS OF DISEASE ACTIVITY 
1. Acute phase reactants. 
2. Pyridinoline cross links from bone. 
C Reactive Protein 
It is an acute phase reactant indicating disease activity in many inflammatory 
disorders.It is used in Rheumatoid arthritis also. CRP was discovered in 1930- by 
Tillet and Francis, in acutely ill patients as a protein that binds with cellwall c-
polysaccharide of Streptococcus pneumonia. 
 It is made up of 5 identical polypeptide subunits.The molecular weight is 
23,028 Da. It is non-covalently associated to form a disc shaped structure with radial 
symmetry. It is related to Serum Amyloid P and pentraxin-3. It has a half life of 18to 
20 hours. 
It provides nonspecific host defence and activates classical complement 
pathway. 
 Serum Concentration of 5-10mg/L suggest inflammation and its rise is 
proportional to tissue damage 19.   
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PRL & IMMUNE SYSTEM 
            Role of PRL in immune system was described as early as 1930s.Prolactin 
known as a lactogenic hormone is a cytokine .In addition to secretion from 
acidophills of anterior pituitary it is also secreted by lymphocytes, deciduas of 
uterus, amnion, chorion of placenta, mammary gland and many regions of brain. The 
role of Prolactin in immune regulation and autoimmune diseases had been explained 
by many invitro and invivo animal and human studies . Prolactin regulates the 
maturation of CD4- and CD8- to CD4+ and CD8+. Prolactin decreases or prevent the 
apoptosis of lymphocytes. Interferes with peripheral tolerance. Prolactin enhances 
the proliferative response to  certain antigens and mitogens. Prolactin upregulates 
the expression of Th1 cytokines. Th1 cytokines are involved in autoimmune 
diseases. 
Let us go through Prolactin hormone in a new aspect. 
PROLACTIN 
Prolactin (PRL) the lactogenic hormone belongs to Group – 1 ‟ helix bundle 
protein hormones”. This group also includes Growth hormone synthesized by 
anterior pituitary and placental prolactin like peptides  synthesised by placenta  22,23    
STRUCTURE 
PRL is made of a single polypeptide chain with 199 AA . Its molecular 
weight  is approximately 23 KDa .It has 3 intramoleclar disulphide bridges cys4- cys 
11, cys58-cys 174, cys 191-cys199 24.Prolactin is arranged as 4 antiparallel alpha 
helix. 25,26  
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SYNTHESIS 
Prolactin is a polypeptide of 199 amino acids synthesized by acidophilic cells 
(‘lactotrophs’) of anterior pituitary gland. It is synthesized as a prohormone with 227 
AA. The cleavage of signal peptide- 28 AA gives mature human prolactin 27,28 
PROLACTIN VARIANTS 
 The normal circulatory serum PRL is monomeric 23KDa form. In addition 
to 23KDa form, many other prolactin variants are also seen in circulation .These 
variants are formed by proteolytic cleavage, post translational modifications, 
alternative splicing of the primary transcript. 27. Alternative splicing is the minor 
contributor to Prolactin pool,it forms a 137 AA long Prolactin 29 
By means of proteolytic Cleavage 14KDa,16KDa and,22KDa fragments are 
produced. They are found in pituitary extracts and  human serum. Their biological 
activities are not well defined. These forms may be preparative artifacts 27. 
The post translational modifications occurring are dimerization , 
polymerization, phosphorylation, glycosylation, sulfation   and deamidation 
30
.Dimerization and polymerization of monomeric prolactin or its aggregation with 
immunoglobulins form macroprolactin whose biological activity is low27. 
Phosphorylation of Prolactin occurs within secretory vesicle of lactotrophs just 
before exocytosis31. Non phosphorylated Prolactin is the active form. Phosphorylated 
Prolactin is the autocrine regulator(inhibitor) of  non phosphorylated Prolactin 
secretion. Phosphorylated Prolactin also inhibits the signal transduction pathways 
activated by Prolactin 32.Glycosylation lowers the biological activity  and clearance 
rate of Prolactin 33    
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PROLACTIN GENE 
Prolactin gene is located in Chromosome 6 . It is 10 kbp with 5 exons and  4 
introns.24,34 This gene has 2 independent promoters. Pituitary specific expression is 
by the proximal 5000 bp promoter 35 . The upstream promoter is concerned with 
extra pituitary expression 36. 
PITUTAIRY PROLACTIN SECRETION: 
Lactotrophs of anterior pituitary secrete Prolactin. TRH responsive 
lactotrophs are present in the outer zone of anterior pituitary 37, whereas dopamine 
responsive acidophils  are present in inner zone of anterior pituitary 38 .  
Figure 4- structure of PRL gene showing two promoter 
 
Courtesy: Mendez etal- Prolactin in the immune system-2013 
AP1: activator protein 1;  C/EBP: CCAAT/enhancer binding protein  
Pit1:pituitaryspecifictranscription factor 1; CRE: cyclic-AMP response element; 
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HoxA-11: homeobox A11;FOXO1A: forkhead box protein O1A; HNF-1: 
hepatocyte nuclear factor 1; ETS: E-twenty six; ERE:estrogen response element. 
Enhancer regions are represented in green. 
OTHER SITES OF PRL SYNTHESIS: 
Many areas of brain ,caudate nucleus, striatum ,non pregnant uterus, 
placenta, amnion, mammary gland,synovium,fibroblast,B and T lymphocytes, NK 
cells,macrophages. 
PROLACTIN RECEPTOR:It is a Cell surface receptor 39 .Prolactin receptors are 
classified as cytokine receptor superfamily classI . 
PRL RECEPTOR GENE:The gene is present in chromosome 5.It is made of upof 
10 exons 40 .This gene have 3 different tissue specific promoters- for gonads , liver 
and gonadal& non-gonadal tissues. 41  
 PRL RECEPTOR DISTRIBUTION IN VERTEBRATES: 42 
PRL receptors are distributed widely. These receptors are present in the 
following regions  
1. Central nervous system   -   Brain cortex, hippocampus, choroid plexus, 
corpus striatum, cochlear duct, corpus callosum ,hypothalamus ,ganglia ,astrocytes 
,retina, olfactory ganglia, anterior & posterior lobes of pituitary.    
2.  Adrenal cortex, Renal cortex, Lungs ,Skeletal muscles, brown adipose tissue, 
submandibular & submaxillary salaivary glands. 
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3. Skin- epidermis ,hairfollicle, sweat gland. Bone- osteoblast, cartilage- 
chondrocytes ,atrial muscles 
4. GIT- Duodenum, jejunum, ileum,colon. Pancreas- islets of langerhans . 
Liver- hepatocytes, kupffer cells  
5. Immune system- spleen, thymus ,T&B lymphocytes , MALT ,NK cells , 
Macrophages  
6. Ovary- ova, granulose cells, thecal cells, Sertoli cells corpus luteum, 
fallopian tubes. Nonpregnant endometrium & pregnant uterus –decidua ,Placenta, 
amnion  
7.  Sperm, seminal vesicle, epididymis, testis, prostate, leydig cells   
TYPES OF PROLACTIN RECEPTOR: 
Many forms of PRL receptors are present. They are formed by alternative 
splicing 43 .Based on size of the intracellular part the receptors are classified as long , 
short and intermediate forms. Soluble forms are also available. 
STRUCTURE OF PROLACTIN RECEPTOR: 
The PRL receptor have  extracellular , transcellular and intracellular domains. 
The extracellular domain has 3 constitutively expressed regions – 
• CRH- Cytokine receptor homology region,CRH is divided into D1 & D2.  
• D1 subdomain – 2 pairs of disulfied linked cysteine present in the N- 
terminal region. 
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• D2 subdomain – Pentapeptide WS motif-( Trp-Ser-X-Trp-Ser) present in 
the C terminal region.  
Proline rich motif( I-F-P-P-V-P-X-P) proximal to transmembrane domain is 
necessary for interacting with Janus Activating Kinase 2 . 44 
Single pass transmembrane domain whose function is unknown. 
Intracellular region has 2 conserved regions- Box1 and Box2 
Box1- It is 8 AA region recognized by transducing molecules. Box1 is rich in 
proline and hydrophobic residues. 
Box2- made of hydrophobic and negatively charged AA 45. 
MECHANISM OF PROLACTIN ACTION: 
Prolactin acts through JAK-STAT pathway.  
JAK is a family of 4 proteins – JAK1, JAK2, JAK3,TyK2 46 
An adapter links JAK2 and PRLR through SH3 domain47.Activation of JAK2 by 
PRL  occurs within 1 minute48 . 
PRLR PHOSPHORYLATION:  Dimerisation of the receptor occurs by binding of 
PRL with its receptor.  This causes phosphorylation of Janus kinase and 
Phosphorylated Janus Kinase  transphosphorylates  the tyrosine residues in each arm 
48
 .All the 3 isoforms are capable of activating JAK 48.Usually phosphorylation of 
473,479 tyrosine residues occur . But in cells with overexpression of JAK2 in 
addition to 473,479 tyrosine residues 309, 402, 515  tyrosine residues are also 
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phosphorylated. Phosphorylation is essential because phosphotyrosine residues are 
essential for binding of  transducer molecules  with  SH2 domain.  
Figure 4 – Activation of PRL receptor 
 
COURTESY:MARC E. FREEMAN, BE´ LA KANYICSKA, ANNA LERANT, 
AND GYO¨ RGY NAGYPHYSIOLOGICAL REVIEWSVol. 80, No. 4, October 
2000 
SIGNAL TRANSDUCTION PATHWAYS activated by PROLACTIN 
The major pathway activated by PRL is STAT-Signal Transducers and 
Activators of Transcription. STAT family of proteins are latent cytoplasmic proteins 
with a molecular weight of 90 to 100 KDa.They are seen bound to intracellular 
domains of cytokine receptors. . STAT family includes 8 proteins- STAT 1α, STAT 
β ,STAT2,3,4,5a,5b,6 .  STAT5a, STAT5b .STAT1 & STAT3 are the Prolactin 
induced transducers. STAT 3 is called as Acute Phase response factor .There are 5 
conservd domains in STAT. They are  DNA binding domain,SH3 like domain, SH2 
like domain ,NH2 & COOH terminal domains . Phosphorylated STAT dissociates 
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from the receptor and form a homo or heterodimer with –SH2 like domain of 
another phosphorylated STAT molecule. 
STAT dimer translocates to nucleus binds with the GAS sequence 
(TTCxxxGAA) – Gamma interferon activated sequence , a DNA binding motif in 
the promoter region of target gene and thus enables transcription 49 . 
              STAT also interacts with other signal transducers thereby initiating cell and 
cytokine specific response 50.The transactivation potential of Stat are modulated by 
interaction of STAT  with nuclear proteins like p48 , IRF-1 , c- jun , sp1 , Src , 
nuclear hormone receptors , MCM5 , BRCA1 51 and with many co- activators 52.Co-
activators are agents that enables  interaction between transcription factors and basal 
transcription machinery components.  The co-activators also activates HAT- histone 
acetyl transferase activity, causing chromatin remodeling ;thereby helps in 
transcription. 
STAT 1 interact with 3 regions in the co-activator protein p300/ cAMP 
response binding protein. 
Other Pathways activated 
Prolactin also activates MAP kinase pathway. Both JAK-STAT and MAPK 
pathways are interconnected 53. Prolactin also acts through Src kinase family, Fyn, 
IRS-1, Phosphatidylinositol- 3- kinase 54. 
TERMINATION OF PROLACTIN SIGNALLING 
Inhibition of STAT activation and catalytic activity of Janus Kinase occurs 
with the help of SOCS- suppressors of cytokine signaling . Prolactin itself induces 
the acute and transient expression of SOCS-1 & 3 55. 
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Other inhibitors are JAB- JAK binding protein, SSI- STAT induced STAT 
inhibitor. These inhibitors act by competing with STAT for binding to the receptor. 
PIAS3- Protein Inhibitor of activated STAT; another inhibitor blocks the binding of 
STAT3 to its DNA targets 56-59 
BIOLOGICAL ACTIONS OF PROLACTIN: 
The distribution of PRL receptors in many regions and secretion of PRL by 
many cells describes its n number of functions 
LACTATION: PRL is necessary for mammopoiseis and lactogenesis . PRL does 
this function by activating Jak2-STAT5 pathway 60. 
LUTEAL FUNCTION: Prolactin is essential in pregnancy for progesterone 
synthesis and luteal cell hypertrophy 61. It has a role in steroidogenesis in granolosa 
cells 62.High levels of prolactin in humans inhibits luteinization 63. 
OSMOREGULATION: Prolactin regulates solute and water transport across cell 
membrane 64. PRL has a role in fluid 65sodium chloride66,calcium 67transport across 
intestinal epithelial membranes.  
ANGIOGENESIS: Intact human Prolactin has anti-angiogenic activity which is 
attributed to 16 KDa fragment of Prolactin .Placental PRL like peptides and  Growth 
hormone has  anti-angiogenic properties 68. 
ROLE AS A MITOGEN :The essential component of an effective immune 
response is antigen driven clonal expansion of T-Lymphocytes . Prolactin is a 
necessary co-mitogen for human T&B Lymphocytes proliferation 69. Acts as a co-
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mitogen for NK cells & macrophages 70 .The cell cycle of lymphocytes is regulated 
by Prolactin , thereby influence the  proliferation of these cells by modulating the 
gene expression 71,72. Devinsetal have shown that in humans, decreasing Prolactin 
levels by dopamine administration results in transient and significant reduction in 
mitogenic response of isolated peripheral lymphocytes to a mitogen 73.   
IMMUNE MODULATION: 
  Prolactin and other pituitary hormones act as stress adaptation molecules and 
they are important in immune system homeostasis 74.Prolactin balances the  effects 
of glucocorticoids and other inflammatory mediators at times of inflammation and 
maintains  the steady state. This is supported by an invitro study where 
glucocorticoid induced  death of lymphocytes was prevented by Prolactin 
75
.Prolactin acts at autocrine, endocrine, paracrine levels in regulating immune 
response 76 . 
                Role of Prolactin in immune response has been demonstrated in 1972 by 
showing that exogenous PRL enhances thymic function in PRL deficient dwarf 
mice77. The significance of Prolactin in immune response  has been emphasized and 
proved by many invitro experimental studies .Immune responses are enhanced by 
Prolactin78.Prolactin receptor expression has been seen in spleenocytes, thymocytes, 
bone marrow cells, PBMC ,lymphocytes and monocytes 61.The constitutive 
expression of PRL and its receptor in resting T- Cells indicate that Prolactin has a 
role even in steady state 79. Granulocytes express PRL transcripts yielding a high 
molecular weight immunoreactive protein similar to pituitary Prolactin  . Prolactin is 
stored as vesicles inside the monocytes and released during infection. 
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Immunohistochemical staining of PBMC has shown the presence of Prolactin in 
vesicles close to the nucleus 80.   
IN-VITRO STUDIES: 
Prolactin receptors are expressed by thymic epithelium. Thymic epithelial 
cells on exposure to ovine prolactin secreted thymulin ,the T-Cell differentiation 
factor 81. Prolactin enhance thymocytes release from thymus 82.Prolactin induces IL-
2 receptors expression on T-Cells 83. Prolactin stimulates growth of immune cells 
when used along with a mitogen. This has been demonstrated in proliferation of 
mouse unfractionated spleen cells, human peripheral mononuclear cells ,Th-T 
Helper cells. Addition of Anti- Prolactin antibodies inhibited the mitogenic response 
in these cell cultures 84,85.This indicates that Prolactin acts as a autocrine or a 
paracrine growth factor 86. Exogenously added prolactin enhanced the expression of  
surface activation markers CD69 and CD25 on human peripheral B lymphocyte  87. 
LYMPHOCYTE AND PROLACTIN : 
Lymphocytes snythesize biologically active form of Prolactin which may act 
as an autocrine and paracrine growth factor 88.  Dexamethasone  inhibits the gene 
expression of both forms of Prolactin 89 .A patient with Acute Myeloid Leukemia 
had hyperprolactinemia, her leukamoid cells were isolated and subjected to 
immunoblotting technique that revealed the presence of Prolactin ,thus Prolactin 
secreted from lymphocytes can contribute to systemic Prolactin concentration 90 .   
IN VIVO STUDIES 
Dinitrochlorobenzene induced dermatitis and antibody responses to T-Cell 
antigen & sheep red blood cells are suppressed in hypophysectomised rats and 
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reversed by prolactin injections 91.Rats completely deprived of Prolactin by 
hypophysectomy and anti- Prolactin antibody developed anergy and anaemia, 
injections of Prolactin reversed spleen and thymic involution by stimulating the c- 
myc pathway 92.Artificial hyperprolactinemia induced in C57BL/6 mice increased 
humoral antibody response to sheep RBC 93.Cysteamine ,a sulfhydryl reducing agent 
reduces serum Prolactin levels. Mice treated with cysteamine developed thymus 
atrophy and reduced response to T & B Cell mitogens 93.Prolactin is a potent 
stimulator of macrophage .INF-γ secretion is increased in humans by administration 
of physiological doses of Prolactin 94 .Hypoprolactinemia was associated with tissue 
depletion of macrophages. Prolactin increases phagocytic activity, release of nitric 
oxide and IL-6 secretion from macrophages in mice  95.It inhibits apoptosis of 
lymphocytes 96.PRL cause proliferation of T- cells either independent of IL-2 or 
with IL-2 97.   
PROLACTIN and IRF-1: 
Interferon Regulatory Factor-1(IRF-1) is a family of nine proteins involved 
in immune response 98. IRF-1 regulates expression of genes that mediate antiviral, 
anti bacterial responses, Th1 responses , macrophage & dendritic cell function , NK-
cell function and differentiation , cell cycle progression and apoptosis 99 .IRF-1 can 
also be considered as a tumour suppressor gene since mutation or deletion in this 
gene causes myelodysplastic syndromes 99. 
            Prolactin modulates IRF-1 expression is evidenced by many in-vitro and in-
vivo studies. Prolactin stimulates expression of IRF-1 in rat leukocytes and human 
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granulocytes 100.PRL alters IRF-1 gene transcription at early G1and G1-S transition 
phase 101 .  
            This is mediated by activated STAT bound to GAS element at -120bp , 
constitutive Sp1 binding at -200bp 102 and interaction with co-activator 
CBP/p300103.Activation of STAT1 cause expression of IRF1 whereas STAT5 
activation causes repression of IRF-1 104 
 PROLACTIN and IL -6: 
Prolactin along with E2 (estradiol)  downregulates glycoprotein 130 component of 
IL-6, as well as its gene expression in deciduas of uterus.  IL-6 expression in decidua 
cause termination of pregnancy 105.Thus PRL conserves pregnancy by acting as an 
immune inhibitor. 
PROLACTIN AND AUTOIMMUNITY: 
The homeostasis of Immune system is maintained by a balance between Th1 
and Th2. Prolactin activates both Th1 and Th2 , influence of Prolactin over Th1 is 
more when compared to Th2. Increased Prolactin levels with either Th1 or Th2 
dominance  has been documented  in many autoimmune diseases. Many animal 
models and human disorders have suggested that Th1 cytokines like TNF-α,INF-γ, 
IL-2 are involved  in organ specific autoimmune diseases like Rheumatoid arthritis 
,multiple sclerosis, insulin dependent Diabetes mellitus. Th2 is associated with SLE, 
Hashimotos throiditis, allergy106 . 
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PRL causes differentiation of monocytes to dendritic cells . Induce T cell 
activation and proliferation , cause imbalance between Th1 and Th2 leading to 
autoimmunity.  Prolactin enhances the Th1 mediated response 107,108    
Figure 5 – PRL in Autoimmune diseases 
 
Courtesy: Mendez etal- Prolactin in the immune system-2013 
RA-Rheumatoid arthritis, MS- Multiple sclerosis, DM- Diabetes Mellitus, HT-
Hashimoto thyroiditis, SLE- systemic lupus erythematosus ; DC-Dendritic cell, BC-
B-lymphocyte 
This figure explains Prolactin involvement in autoimmune diseases.  
          Prolactin exerts immuno-stimulatory  effect.PRL Promotes autoimmunity by 
mechanisms such as impaired negative selection of self reactive B- lymphocytes 
during maturation 109.The immune cells are made anti-apoptotic and  proliferative 
response to antigens are enhanced by Prolactin. Thus increased production of 
immunoglobulins, cytokines  increases  the propensity  towards autoimmunity. In 
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murine models association between Prolactin levels and disease progression has 
been seen .Moderate hyperprolactinemia has been seen in Systemic Lupus 
Erythematosus, Rheumatoid arthritis, sjogren’s syndrome ,Hashimoto’s thyroiditis 
,multiple sclerosis 110-113.  
PROLACTIN AND RHEUMATOID ARTHRITIS 
 In a study Prolactin and Prolactin / Cortisol ratio was elevated in active RA 
along with elevated proinflammatory cytokines 26. The diurnal rhythm in disease 
activity of Rheumatoid arthritis is attributed to diurnal variation of  Prolactin 
secretion 27.Prolactin concentration in synovial fluid and serum of RA patients were 
elevated . Serum Prolactin in many autoimmune diseases were shown to be high by 
many studies. 
PROLACTIN AND STRESS 
Mild elevation in prolactin levels occurs in stress. PRL secretion parallels 
with  corticotropin releasing factor secretion; this is necessary for maintenance of 
overall metabolism and survival at times of stress122.Inhibition of immune responses 
by  glucocorticoids is mediated by apoptosis of lymphocytes 123.PRL in culture 
inhibits (Dex)-Dexamethasone induced apoptosis of normal murine thymocytes. 
Thus PRL and glucocorticoids appear to antagonize their respective actions. 
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Figure 6 – PRL antagonizes Glucocorticoid effects and maintains balance. 
 
Courtesy: Prolactin receptor signal transduction in cells of the immune system C V 
Clevenger, D O Freier and J B Kline, Journal of Endocrinology (1998) 157,  
187–197 
Another evidence is reactivation of EBV in  students (examination stress) 
suggested by elevated EBV IgG ,with mild elevation of Prolactin. Since the 
Prolactin levels are not as high as the rise in cortisol, control of T- cytotoxic 
lymphocytes over EBV is lost leading to reactivation of EBV125.  At concentrations 
of 5 to 30 ng/mL, Prolactin increases the secretion of IFN-γ,IL-12 124,125.  
REGULATION OF PROLACTIN SYNTHESIS IN THE IMMUNE SYSTEM: 
  Alternative promoter drives expression of Prolactin in extra-pituitary tissues 
.The distal transcription start site is independent of pit-1 –pituitary transcriptional 
factor.  The extra pituitary Prolactin m-RNA is  ~ 150 bp longer than pituitary 
Prolactin m-RNA 126,127. 
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In Lymphocytes Prolactin expression is independent of pit-1, progesterone 
estrogen,   TRH, dihydrotestosterone, insulin . PRL expression is stimulated by 
cAMP, retinoic acid  , calcitriol .PRL expression is Inhibited by dexamethasone , IL-
2 , IL-4 , IL-β . 
cAMP and PRL 
Action of PRL through cAMP has been studied in certain Leukemic cell 
lines and normal human PBMC. The 1st messengers employed were PGE2, β2 
adrenergic agonist. It acts through cAMP/PKA pathway – phosphorylates 
CREB(cAMP response element binding protein 128 
CALCITRIOL and PRL : Calcitriol effects in the immune system occurs at the 
level of  T- helper cells.Calcitriol acts as an immunosuppressor. It mainly curbs Th1. 
The ability of calcitriol to ameliorate autoimmune diseases and inhibition of 
allograft rejection responses stand as a evidence for cacitriol action on Th1 
cytokines 129.130.Prolactin secretion may be regulated by locally produced calcitriol 
in some granulomatous diseases, which are documented with elevated 
Prolactin131,132. Calcitriol stimulates PRLm-RNA and protein production in resting 
PBMC through a VDR – mediated mechanism133. 
CYTOKINES REGULATING PRL SECRETION: 
IL- 2, IL-4,IL-1β  reduce PRL  m-RNA expression in T Lymphocytes. TNF 
–α stimulates Prolactin release. Stimulation of Prolactin secretion by TNF-α is 
inhibited by protein kinase C inhibition 134. 
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DOPAMINE AND PROLACTIN FROM IMMUNE CELLS: 
The dopamine receptors – D2, D3, D4, D5 are present in peripheral 
lymphocytes 135. D3 receptors are present in secondary lymphoid systems . 
Dopamine regulates expression of its own receptor and Prolactin in PBMC 136 .  
REGULATION  OF PITUITARY PROLACTIN SECRETION :  Prolactin 
secretion is pulsatile with 4 to 14 secretory pulses of increasing amplitude after  
onset of sleep ; declines shortly after awakening  with nadir around noon . Prolactin 
secretion results from removal of Dopamine inhibition and these Prolactin releasing 
factors act by removing the inhibition over TIDA system137. 
Dopamine is the main regulator of pituitary Prolactin release.It acts by 
inhibiting the PRL release. All other peptides regulating Prolactin  act  indirectly  via 
dopamine. 
Both central dopaminergic  and nor-adrenergic  systems( Serotonin , 
histamine , epinephrine,nor epinephrine)  along with estrogen and thyroxine  
regulates prolactin secretion from the pituitary 
Tyrosine hydroxylase enzyme is absent in Anterior pituitary hence dopamine 
has to reach anterior pituitary through TIDA or Tuberohypophyseal system. 
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I] Pathways of Dopamine reaching Anterior pituitary 
1. Tuberoinfundibular dopamine pathway 
ARCUATE  NUCLEUS   TIDA neurons  MEDIAN EMINENCE            PORTAL  
                                                                                                           CIRCULATION            
                                          
ANTERIOR PITUITARY 
2. Tuberohypophyseal system: 
Nucleus preopticus periventricularis, rostral part of arcuate nucleus                     
 
                                                anterior pituitary 
II] Beta  adrenergic regulation of pituitary prolactin secretion:  
Beta adrenergic agonist  stimulates prolactin release. The pathway is  
Nucleus reticularis lateralis + Nucleus tractus solitaries                 Medulla oblongata             
                                                                                                      portalsystem 
                                                                                                                   
Anterior Pituitary 138 
OTHER  FACTORS  INVOLVED IN REGULATION OF SYNTHESIS  
A. OXYTOCIN : It increases prolactin levels by inhibiting TIDA system 
through vaso active intestinal polypeptide137 
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B. SEROTONIN: Serotonin affects Prolactin levels through one or more of the 
Prolactin releasing factors like vaso active intestinal polypeptide( VIP), 
oxytocin(OT),Vasopressin,Thyroid stimulating hormone . Serotonin exhibits its 
effect through 5HT1A receptor. It acts by enhancing adenylate cyclase activity, 
increasing the gene expression of Prolactin.138 
C. GABA: Acts through Tuberoinfundibular GABA system. Inhibition of TIDA 
cells occur by serotonergic stimulation of GABA interneurons.139 
D. TRH: Role of TRH in PRL secretion  is unresolved . May act through 
Protein Kinase C pathway.137 
TRH stimulates Gq , G11 
 
Activation of membrane bound Phospholipase c 
 
Cleaves Phosphatidyl inositol 4,5 bisphosphate to inositol tri phosphate & diacylglycerol 
Mobilizes non mitochondrial calcium in lactotrophs             activates Ca dependent 
               Protein Kinase C                                    
 
                                                                                                  Phosphorylates voltage  
                                                                                          sensitive  Ca channels 
  
                                                                                                 Increase calcium influx 
 
                                                                                           Prolactin exocytosis. 140 
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E.HISTAMINE: Mediated by dopaminergic aswellas serotoninergic neurons 141 
F.OPIODS : Regulate Prolactin secretion by synchronizing pulsatile pattern of 
prolactin release142 
G.ESTROGEN AND PROLACTIN 
         Estrogen causes increased prolactin by reducing dopamine synthesis. 
• Estrogen reduces tyrosine hydroxylase activity 
• Decrease gene expression in Tubero infundibiular dopaminergic neurons 
• Decrease dopamine concentration in arcuate nucleus. 
• Decreases the basal and stimulated Dopamine release from median eminence 
HYPERPROLACTINEMIA 
Hyperprolactinemia is the most common endocrine disorder of hypothalamic 
– pituitary axis 143-145.Expected rate of hyperprolactinemia in normal population is 
upto 3% 106.  Defined as ˃ ˃20ng/mL in male and 25ng/mL in female atleast 2 hours 
after waking up146.Prevalence ranges from 0.4% in an unselected adult population to 
as high as 9 to 17% in people with reproductive diseases 144 .About 40% of primary 
hypothyroid patient, 30% of chronic renalfailure patients, 80% of patients on 
hemodialysis have elevated Prolactin in serum. Many medications cause Prolactin 
levels to rise above 100ng/mL146. 
Macroprolactin 
The predominant isoform in healthy subject and prolactinoma patients is 
Monomeric  PRL-23 KDa, it contributes 80% of the serum prolactin . The remaining 
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20% is contributed by the big prolactin 45 to 60 KDa and big-big or macroprolactin 
150 to 170 KDa 147-148.Many studies show hyperprolactinemia is due to 
macroprolactin because of low renal clearance and decreased stimulation of 
dopaminergic tonus 149.Gold standard for diagnosis of macroprolactin is Gel 
filtration chromatography . Screening method for macroprolactin detection is by 
serum precipitation with Polyethyleneglycol(PEG) 150,151. 
CAUSES OF HYPERPROLACTINEMIA 
I. Physiological causes 
Pregnancy; lactation; stress; sleep; coitus; exercise 
Pregnancy and breast feeding are the most common cause for 
hyperprolactinemia in females . 
Psychological stress causes minimal elevation of serum Prolactin levels .The 
other forms of  stress like physical discomfort, exercise, hypoglycemia ,surgery , 
fear of venipuncture , myocardial infarction are potent stimulus for Prolactin release  
II. Pathological causes 
a. SYSTEMIC DISEASES   
Primary hypothyroidism, adrenal insufficiency, PCOS, renal insufficiency,  
cirrhosis, pseudocyesis, epileptic seizures 
b. HYPOTHALAMIC DISEASES  
• Tumors             : craniopharyngiomas, dysgerminoma, meningiomas, etc. 
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• infiltrative disorders : histiocytosis, sarcoidosis, etc. 
• metastasis 
• cranial radiation 
• Rathke’s cleft cysts, etc. 
c. PITUITARY DISEASES  
 Prolactinomas; acromegaly; thyrotropinomas; Cushing’s disease; infiltrative 
disorders; metastasis; lymphocytic hypophysitis; emptysella syndrome, etc. 
d. STALK DISORDERS  
Hastitis; seccion; traumatic brain injury (TBI) 
e. NEUROGENIC  
• Chest wall lesions: burns, breast surgery, thoracotomy, nipplerings, herpes 
zoster; etc 
• Spinal cord injury : cervical ependymoma, tabes dorsalis, extrinsic tumors, 
etc. 
• Breast stimulation 
f. ECTOPIC PROLACTIN PRODUCTION   
Renal cell carcinoma, ovarian teratomas, Gonadoblastoma, non-Hodgkin 
lymphoma, uterine cervical carcinoma; colorectal adenocarcinoma, etc. 
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III.   Idiopathic 
 IV. Macroprolactinemia 
V.  Drug-induced hyperprolactinemia 
• Antipsychotics: 
            Typical – Phenothiazines; butyrophenones; thioxanthenes 
            Atypical – Risperidone; molindone; amisulpride; quetiapine; olanzapine 
• Antidepressants: 
            Tricyclics – Amitriptyline; desipramine; clomipramine 
            MAO inhibitors – Pargyline; clorgyline 
             SSRIs – Fluoxetine; citalopram; paroxetine 
• Antihypertensive drugs: Verapamil; a-methyldopa; reserpine; labetolol 
• Anticonvulsivants: Phenytoin 
• Prokinetic agents: Metoclopramide; domperidone 
• Others: Estrogens; anesthetics; cimetidine; ranitidine; opiates; methadone; 
morphine; apomorphine; heroin; cocaine; marijuana; alcohol; sibutramine, 
etc 
MECHANISM OF HYPERPROLACTINEMIA BY DRUGS 
Drugs act by altering the dopamine or serotonin or GABA metabolism either 
act directly or via some peptides like VIP, hormones – estrogen etc. 
Atypical antipsychotics are the most common cause of drug induced 
hyperprolactinemia. Antipsychotic drugs decrease dopamine kevels or Dopamine 
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receptors in the CNS. Antidepressants affect serotonin metabolism. 
Antihypertensives act by influencing the adrenergic neurons or on calcium fluxes. 
These are some of the mechanisms through which drugs act. 
ESTIMATION OF SERUM PROLACTIN 
Though Prolactin concentration varies throughout the day time of the day is 
not critical in its measurement 152.Supine position prior to sampling is not 
mandatory. Vigorous exercise and nipple stimulation has to be avoided  for atleast  
30 minutes  before sample withdrawal153.Even the fear of veinpuncture can cause 
mild increase in Serum prolactin (40-60ng/mL)154. 
Diagnosis of hyperprolactinemia can be made when prolactin levels on two 
separate occasions are more than the standard upper limit of normal range 20-
25ng/mL155.Even a single normal value has to be considered as normal ; an isolated 
raised level is usually spurious 156.  
Repeat sampling  at 15 to 20 minutes interval for 3 to 4 times another day 
would account for possible prolactin pulsality 157.To rule out prolactin elevation as a 
result of vein puncture, sample has to be collected from an indwelling catheter after 
2 hours of rest . Sample need to be obtained at 20 minutes interval for the ensuing 2 
hours 152. 
A single determination is usually sufficient to establish the diagnosis when 
the levels are more than 100ng/mL 157.  
Thus by reviewing the literatures the significance of Prolactin in immune 
regulation and its role in Autoimmune disease was understood. Hence this study was 
carried out. 
AIMS & OBJECTIVES 
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AIM OF THE STUDY 
The aim of the study is to assess the concentration of Prolactin in serum of 
the patients with recently diagnosed rheumatoid  arthritis and to correlate serum 
Prolactin levels in those patients with disease activity  
The objectives of the study include  
• To compare the Serum Prolactin concentration in patients with recently 
diagnosed Rheumatoid arthritis with apparently healthy individuals. 
• To correlate Serum Prolactin concentration levels with Rheumatoid Factor,  
Anti CCP antibodies and Erythrocyte Sedimentation Rate. 
MATERIALS & 
METHODS 
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MATERIALS AND METHODS 
This study was conducted following ethical committee approval from 
institutional ethics committee, Madras Medical college held on 11.12.2013 .The 
approval is enclosed. Volunteers were enrolled only after obtaining informed 
consent, a copy of the informed consent and the information sheet regarding the 
study is enclosed . 
STUDY DESIGN : CASE – CONTROL STUDY         
CASES : 55 recently diagnosed Rheumatoid arthritis patients by the 
Rheumatologists in the Rheumatology OPD according to ACR criteria 2010.  
CONTROLS: Apparently healthy volunteers among the staff and students of Madras   
Medical College . 
STUDY CENTRE: Department of Rheumatology & Institute of Biochemistry, 
Madras Medical college. 
STUDY PERIOD : January 2014 – September 2014 
INCLUSION CRITERIA : Recently diagnosed  Rhematoid arthritis patients by 
American college of Rheumatology(ACR) criteria 2010 . 
EXCLUSION CRITERIA  
1. Rheumatoid arthritis patients already on treatment- steroids, NSAIDS, 
DMARDS. 
2. Pregnant and lactating mothers , infertile individuals .Women on oral 
contraceptive pills. 
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3. PCOS, Hypothyroidism, renal failure, diabetes mellitus, hypertension. 
4. Other autoimmune diseases, any chronic illness . 
5. Individuals with signs and symptoms of hyperprolactinemia,  pituitary 
microadenoma, macroadenoma. 
6. Patients on H2blockers, dopamineagonist, antipsychotics, isoniazid, 
antidepressants, Anticonvulsants ,calcium channel blockers, chemotherapy, 
hormone replacement therapy, methyl dopa , cannabis abuse 
7. People with recent chest wall trauma or irritation/ pain  in chest region 
PARAMETERS  ASSESSED  
1. Clinical examination – number of swollen and tender joints. 
2. Hemoglobin , ESR , CRP , RF 
3. Disease Activity Score DAS (28)3  
4. Serum Urea, Serum Creatinine  
5. Serum Thyroid stimulating hormone 
6. Serum Prolactin, Serum Anti cyclic citrullinated  peptide. 
STUDY SUBJECTS SELECTION    
1. The patients attending Rheumatology OPD with symptoms of  early morning 
stiffness of more than 1 hour , symmetrical joint involvement – pain, 
tenderness , swelling in the joints above 20  years of age , clinically 
diagnosed as Rheumatoid arthritis were considered. 
2. They were seated , height , weight and blood pressure measured. 
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3. The swollen and tender joints counted. 
4. Hemoglobin , ESR , Rheumatoid factor , CRP of these patients are 
determined in the Rheumatology department and we have used those data for 
this study. 
5. 5 ml of peripheral venous  blood collected from these patients by applying 
tourniquet. 
6. Samples are collected around 9.00 am  to avoid diurnal variation of prolactin 
in  fasting state .  
7.  Subjects with elevated TSH > 5µIU/mL, creatinine , urea were excluded . 
8. In controls ; individuals with negative CRP , RF , ESR  ≤10 mm in 1 hr are 
included. 
SAMPLE PROCESSING 
Serum was separated by centrifugation at 3000 rpm/min for 10 minutes after 
clot formation. Serum was aliquoted and stored at -20˚c in the deep freezer until 
analysis of Prolactin and Anti  CCP antibody.Remaining  analytes are assayed as the 
samples are collected. 
DAS – disease activity score calculation164  
Disease activity score was calculated using 
DAS = [0.56*√T28 + 0.28* √S28 + 0.7* ln (ESR)]* 1.08 + 0.16  
T- no of tender joints, S- no of swollen joints. 
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Gradesof  Disease activity 
< 3.2        low activity 
3.2 – 5.1  moderate activity 
> 5.1         high activity  
 
ACR / EULAR Criteria 2010 : Diagnostic criteria for Rheumatoid arthritis170 
Includes clinical & serological variables. The total points need to be more 
than or equal to 6 to have a diagnosis of Rheumatoid arthritis. 
• JOINT INVOLVEMENT  
Small joints :- metacarpophalangeal joints, proximal interphalangeal joints, 
the interphalangeal joint of the thumb, second through fifth metatarsophalangeal 
joint and wrist  
Large Joints shoulders, elbows, hip joints, knees, and ankles  
1 large joint                                                                                         0 point  
2–10 large joints                                                                                  1 point 
1–3 small joints (with or without involvement of large joints)          2 points 
4–10 small joints (with or without involvement of large joints)       3 points 
 More than 10 joints (with involvement of at least 1 small joint)       5 points 
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SEROLOGICAL PARAMETERS –  Rheumatoid factor , ACPA – "ACPA" 
stands for "anti-citrullinated protein antibody": 
• Negative RF and negative ACPA                     0 points 
• Low-positive RF or low-positive ACPA          2 points 
• High-positive RF or high-positive ACPA        3 points 
Acute phase reactants 
Elevated erythrocyte sedimentation rate ESR / elevated CRP value (c-
reactive protein) 1 point 
Duration of arthritis 
  For symptoms lasting six weeks or longer – 1 point 
SERUM PROLACTIN  ESTIMATION 
METHOD: ELISA- Sandwich method 
Kit Manufacturer : Pathozyme - Omega diagnostics 
PRINCIPLE  
1. Anti Prolactin antibodies are coated on the microtitre walls. 
2.  Test sera are applied. 
3. Monoclonal anti Prolactin labeled with horse radish peroxidase enzyme-
conjugate is added. 
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4. Human Prolactin present in serum binds with horse radish peroxidase labeled 
anti Prolactin and anti Prolactin bound with microtitre walls. Thus Prolactin 
is sandwiched between 2 antibodies. 
5. After incubation the unbound materials are washed away. 
6. The substrate TMB is added, will be acted upon by horse radish peroxidase 
enzyme present in sandwich complex and a colour change occurs indicating 
the presence of Prolactin. 
7. The reaction is stopped by the addition of dilute hydrochloric acid. 
8. Absorbance is measured at 450 nm, the concentration is directly proportional 
to the colour developed. 
MATERIALS REQUIRED 
1. Anti- Prolactin   coated microtitre plate – 96 wells. 
2. Conjugate – Anti – Prolactin HRP  conjugate . 
3. Substrate solution – 3,3’,5,5’ Tetramethyl benzidine in citrate buffer. 
4. Stop solution – 1 M HCl, hydrochloric acid dissolved in  deionised water. 
5. Calibrators:  
 Cal A 0 ng/mL Lyophillised human serum free of Prolactin. 
Cal B 5 ng/mL Prolactin diluted in human serum – 
lyophillised. Cal C 15 ng/mL 
Cal D 50 ng/mL 
Cal E 100 ng/mL 
Cal F 200 ng/ mL 
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6. Micropipettes - 100µL, 200 µL, 1000µL 
7. Disposable pipette tips. 
8. Absorbent paper. 
9. Microtitre plate reader with 450 nm 
Reagent preparation  
1. All reagents are brought to room temperature. 
2. 1 ml of distilled water is added to standard vials and made to stand for 20 
minutes, then mixed gently. 
3. All other reagents are ready to use. 
PROCEDURE 
1. 50 µL of standard are pipetted in the1st 6 wells and study subjects serum 
added in the remaining wells. 
2. 100 µL of conjugate added in all wells , mixed for 10 seconds. 
3. Incubated for 45 minutes at 20 -25˚c. 
4. Machine washing is done 5 times using distilled water, 300 µL distilled 
water is used per cycle for each well. 
5. The remaining fluid present in wells are removed by striking the wells 
against absorbent paper. 
6. 100 µL of substrate solution is added in each well, gently shaken for 5 
seconds. 
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7. Incubated in dark for 20 minutes. 
8. 100 µl of stop solution is added in each well, gently shaken for 30 seconds. 
9. Optical density is measured at 450nm in ELISA reader .  
Calculation of results 
1. The  standard curve is plotted using concentration along x – axis & 
absorbance along  y- axis 
concentration 
ng/mL, PRL 
 
absorbance 
0 0.0738 
5 0.1071 
15 0.1678 
50 0.4129 
100 0.6686 
200 0.9279 
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Using the absorbance values for each sample the concentration is calculated with the 
help of standard curve.  
                         Anti Citrullinated Peptide Antibody( Anti CCP)    
METHOD: ELISA- Sandwich 
KIT manufacturer :  G.E.N.E.S.I.S Diagnostics 
Principle 
1. Diluted serum samples are incubated with recombinant citrullinated rat 
fillagrin immobilized on microtitre plate wells. 
2.  The unbound serum components are washed,rabbit anti-human IgG 
conjugated to horse radish peroxidase is added which binds with surface bound 
antibodies on incubation. 
3. Unbound conjugate is removed by washing. 
4.  TMB –substrate is added,incubation allowed for the reaction to take place. 
5. Then stop solution is added and optical density is measured at 450 nm, 
colour developed   is directly proportional to concentration of anti ccp. 
Materials required 
1. Recombinant citrullinated rat fillagrin coated  microtitre plate – 96 
wells. 
2. Sample diluent- 150 mM Tris-buffered saline,pH- 7.2 with 
antimicrobial agent. 
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3. Wash buffer – 100 mM,Tris buffered saline with detergent ,pH- 7.2 
4. Conjugate – rabbit antihuman IgG conjugated to horse radish 
peroxidase in protein stabilizing solution and antimicrobial agent. 
5. Stop solution- 0.25M sulphuric acid. 
6. Standards- 0,6.25,12.5,25,50,100 U/mL in 1mL of 10mM Tris- 
buffered saline containing human serum IgG antibodies to 
citrullinated protein.    
7. Positive control  
8. Negative control 
9. Disposable micropipette tips, 10µL & 100µL micropipettes 
10. Absorbent paper, de-ionised water. 
REAGENT PREPARATION  
1. Sample diluent – 1: 14, 14 parts of distilled water. 
2. Wash buffer- 1: 9, 9 parts of distilled water. 
Sample Preparation  
      Serum diluted with sample diluent in 1:100, 100 parts of sample diluent. 
PROCEDURE 
1. The standards, controls , diluted samples - 100µL are pipetted  in to 
appropriate wells. 
2. Incubated for 30 minutes at room temperature. 
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3. After 30 minutes , machine washing is done. 
4. Then 100µL of conjugate is added,incubated at room temperature for 30 
minutes. 
5. Machine washing is done. 
6. 100µL of TMB substrate is added, incubated in dark for 10 minutes. 
7.   100µL of stop solution is added 
8. The optical density is read at 450 nm in ELISA reader. 
Calculation 
1. The  standard curve is plotted using concentration along x – axis & 
absorbance along  y- axis 
standards Conc U/mL OD 
1 0 0.038 
2 6.25 0.316 
3 12.5 0.580 
4 25 0.898 
5 50 1.383 
6 100 1.860 
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3. Using this standard curve the concentration is calculated . 
THYROID  STIMULATING HORMONE 
METHOD: - Immuno enzymometric assay 
KIT manufacturer :  Biotron 
PRINCIPLE:  The immobilization of antigen occurs during the assay. The well is 
coated with streptavidin.  TSH in the serum forms a complex  with  Enzyme labeled 
Polyclonal Anti- TSH and BIOTIN labeled MONOCLONAL Anti TSH.This 
sandwich of TSH(Ag) between  two antibodies  binds to streptavidin coated wall by 
means of biotin labeled monoclonal anti TSH.  
1.Ag+ E-poly Ab+B-mono Ab                        B-monoAb-Ag-poly Ab-E. 
2.Streptavidin –B-monoAb-Ag-polyAb-E    - immobilized complex 
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Ag- TSH 
E-poly Ab- Enzyme labeled polyclonal antibody 
B-monoAb- biotinylated monoclonal antibody 
3. The unbound fraction are separated. 
4. The enzyme activity determined by addition of substrate, the colour 
developed is directly  proportional to the concentration of TSH. 
MATERIALS REQUIRED 
1. Streptavidin coated plate (96 wells). 
2. TSH enzyme reagent 
3. Wash solution  
4. Substrate A 
5. Substrate B 
6. Stop solution 
7. Micropipettes 50& 100µL 
8. Disposable tips, absorbant paper 
9. ELISA reader 
10. 7 standards 0,0.5,2.5,5,10,20,40 (µIU/mL) 
11. Control – 7.7 µIU/mL 
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REAGENT PREPARATION 
1. WORKING SUBSTRATE: equal volumes of substrate A & B are mixed and 
need to be used immediately. 
2.  Wash buffer: The wash concentrate is diluted to 1000ml with distilled water. 
PROCEDURE 
1. 50µL of sample, standard, control are pipetted  in to the corresponding wells.  
2. 100 µL of TSH enzyme reagent is added. 
3. The plate is swirled gently for 12 seconds ,then incubated at room 
temperature for 60 minutes. 
4. Machine washing done- 3 cycles  using 300µL of wash buffer per cycle 
5. 100 µL of working substrate ( freshly prepared) is added. 
6. Incubated at room temperature for 15 minutes. 
7. 50µL of stop solution is added. 
8. Mixed gently for 10 seconds 
9. Absorbance measured at 450 nm, refence wavelength -620 nm in ELISA 
reader. 
CALCULATION  
1. Graph is drawn using concentration along x axis and absobance along y axis. 
2. Using this graph the concentration of individual samples are calculated. 
 
 
68 
 
conc absorbance 
0 0.019 
0.5 0.088 
2.5 0.32 
5 0.56 
10 0.89 
20 1.532 
40 2.647 
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RHEUMATOID FACTOR  ( semi Quantitative method) 
METHOD: Latex Agglutination 
KIT  Used : ACCUCARE 
PRINCIPLE: Rheumatoid factor present in serum agglutinates the latex particles 
coated with human gamma globulin.If the rheumatoid factor level in serum is greater 
than 8 IU/mL, agglutination will occur.  
MATERIALS REQUIRED 
1. RF Latex reagent 
2. Positive control 
3. Negative control 
4. Glass slides 
5. Stirrer rods 
6. Droppers 
PROCEDURE 
1. 1 drop of serum,1 drop of positive control, 1 drop of negative control are 
added in different circles on the slide 
2. RF Latex reagent is added in all the circles. 
3. Stirrer is used to mix and spread the contents in test circle. 
4. The slide is rotated and observed for agglutination with in 2 minutes. 
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5. The samples showing agglutination are positive for Rheumatoid factor. 
6. These samples are quantitated  by diluting with normal saline. 
7. Samples in these dilutions 1:2,1:4,1:8,1:64 are prepared and subjected to the 
above described method until there is no agglutination  .   
CALCULATION 
RF = Highest dilution with positive reaction * 8 IU/mL ( reagent sensitivity) 
C Reactive Protein  ( Qualitative) 
METHOD : Latex Slide agglutination. 
KIT used : Pathozyme 
PRINCIPLE: CRP in the serum binds with latex particles coated with monospecific 
anti human CRP. Sensitized to detect levels greater than 6µg/mL. 
MATERIALS REQUIRED 
1. CRP Latex reagent. 
2. Positive control 
3. Negative control 
4. Disposable droppers, sample applicators. 
5. Glass slide 
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PROCEDURE 
1. One drop of serum is added on the slide 
2. Then one drop of CRP Latex reagent is added. 
3. Gentle to and fro motion is made and watched for macroscopic agglutination 
with in 2 minutes. 
RESULTS 
      1.  Coarse agglutination – strongly positive 
      2.   Finer  agglutination -  weakly positive 
      3.   smooth suspension/ no noticeable change - negative  
ESTIMATION OF CREATININE (auto analyser) 
METHOD: Modified Jaffe’s  reaction. 
Kit Used : Erba Mannheim XL System Packs 
PRINCIPLE :  Creatinine reacts with alkaline picrate to produce a reddish orange 
colour. This is a non specific reaction . 
REAGENT COMPOSITION 
R1   Sodium hydroxide – 240 mmoles/L 
R2    Picric acid  - 26 mmoles/L. 
CALIBRATION: Done with serum based XL multical calibrator. 
 
72 
 
ASSAY PARAMETERS: 
Primary wavelength  –  505 nm 
Secondary wavelength–  570 nm 
Assay type   –  Rate A 
Curve type   –  Linear. 
R1 volume   –  160 µL 
R2 volume   –  40 µL 
Sample volume  –  10 µL. 
CALCULATION : Results are calculated automatically by the instrument. 
ESTIMATION OF UREA ( autoanalyser) 
METHOD:  Urease – Glutamate dehydogenase. 
Kit Used : Erba Mannheim XL System Packs 
PRINCIPLE  
Urea is hydrolysed by urease enzyme to ammonia and carbon di oxide in the 
presence of water. 
                               Urea + H2O      Urease           NH3 + CO2 
Ammonia combines with α – ketoglutarate in the  presence of  NADH to give 
glutamate & NAD 
\NH3+ α ketoglutarate + NADH    Glutamate dehydrogenase   L- Glutamate + NAD 
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The reaction is monitored by measuring the rate of  decrease in absorbance at 340 
nm due to formation of NAD. 
REAGENT COMPOSITION 
R1   Tris buffer   100mmol/L 
        Alpha – ketoglutarate       5.49 mmol/L 
         Urease ( Jack Bean)         ≥ 10KU/ L             
         GLDH ( microorganism) ≥2.5KU/ L 
R2    NADH      1.66 mmol/L 
CALIBRATION : Done with  serum based  xL multical calibrator. 
ASSAY PROCEDURE: 
Primary wavelength       340 nm 
Secondary wavelength   415 nm 
Assay type                      Rate A 
Curve type                      Linear 
R1 volume                      160µL 
R2 volume                       40µL 
Sample volume 2 µL 
CALCULATION : Results are calculated automatically by the instrument 
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ERYTHROCYTE SEDIMENTATION RATE. 
METHOD  
Conventional Westergrens method. 
PROCEDURE 
1. EDTA anticoagulated blood is drawn upto 200mm mark in the westergrens 
tube. 
2. The tube is placed vertically and left undisturbed for 60 minutes. 
3. The cells get sedimented , the nearest 1 mm is read just above the sedimented 
cells . 
The measured reading is ESR, expressed in mm in 1 hr. 
STATISCAL ANALYSIS 
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STATISTICAL ANALYSIS 
 Statistical analysis was performed using SPSS software version 20 and the 
following were carried out  
• Tests of significance at 5% significance using Unpaired students’t-test was 
done to compare the Serum Prolactin between cases and controls. 
• Pearsons correlation co-efficient was done to measure the linear relation   
relationship between serum prolactin concentration and other parameters like 
DAS28(3), ESR , Anti CCP, ACR score , Symptom duration , Age.  
•  One Way - ANOVA  Analysis of Variance to compare more than 2 
variables in the same group & between groups was carried out to compare 
serum prolactin concentration between four groups viz- RF & Anti CCP 
positive, RF positive Anti CCP negative , RF negative Anti CCP positive , 
RF & Anti CCP negative. 
RESULTS 
sym.dur crp esr RF RF values ACR score das PRL Anti CCP TSH µIU/ml hb menstruation ureamg/dL creatinine mg/dl ht cm wgt kg Bp mm of Hg
4 mths neg 16 pos 5 6 4.5 4 2.27 1.5 9.8 post 27 0.7 152 55 130/80
2 mths pos 30 pos 8 8 4.8 15.6 3.87 1.3 10 post 24 0.8 156 60 120/70
8mths pos 10 pos 130 7 4.1 30 192.17 1.8 8.5 11th day 18 0.7 155 62 120/70
9mths pos 10 neg 6 4.2 30.9 4.64 1.2 9.5 19 1.2 168 70 130/80
2mths pos 14 neg 7 3.79 32 102 3.32 10.4 6th day 25 1 150 57 130/80
8mths pos 44 neg 7 5.67 37.7 29.12 3.6 9.5 post 20 1.1 156 65 140/80
12mths pos 66 pos 138 10 7.73 21.4 182.32 3.2 8.5 3rd day 27 0.7 160 65 122/70
6mths pos 28 pos 140 6 3.96 16 198.67 1.3 10.2 26th day 28 0.9 161 56 130/80
6mths pos 26 neg 6 5.49 28 22.6 2 11.6 6th day 26 0.8 164 59 120/80
3mths pos 34 neg 7 4.64 42 9 1.2 9.8 32 1 170 60 130/80
2 mths neg 22 neg 6 4.13 33 23.79 1.8 10.2 3rd day 25 0.8 154 63 120/80
3mths neg 15 neg 6 3.49 27 23.12 3.5 11 21 1.3 158 56 130/80
2 mths neg 10 neg 6 5.04 28 27.48 1.3 9.8 11th day 26 1 149 58 120/80
3mths pos 50 neg 7 5.98 16.2 4.38 1.5 9.8 post 28 1.2 157 59 126/80
2 mths neg 4 neg 7 5.17 12.5 6.5 5.5 10.5 11th day 36 1.1 152 60 130/70
3mths pos 165 neg 7 6.89 54.9 24.75 1.2 11.6 21st day 32 0.8 154 56 120/70
2 mths neg 20 neg 7 5.29 28 140.8 2.1 10 11th day 24 0.5 150 54 120/80
4mths pos 90 neg 7 6.57 50 24.83 1 9.2 post 20 1.2 156 55 120/80
6mths pos 30 neg 6 5.59 33.6 20.5 1.2 8.5 post 22 1.2 148 43 130/80
4mths pos 64 pos 32 6 6.6 34 35.4 3.6 11.8 9th day 27 1 151 48 120/70
8mths pos 60 pos 191.8 10 6.43 55.8 7.6 2.3 9.2 11th day 21 0.7 153 54 130/80
4mths pos 65 neg 7 6.18 24.6 8.1 1.8 10.4 post 24 0.9 150 49 120/70
3mths pos 10 neg 6 4.03 22.2 7.54 3.2 9.6 22nd day 29 0.5 152 56 130/80
3mths pos 38 neg 6 4.72 24.4 19.14 0.9 11.2 24 1.3 169 59 120/80
5mths neg 60 neg 6 6.94 20.8 3.68 2.2 12 31 1.1 165 61 110/70
3mths pos 100 neg 7 7.05 29.8 8.89 1 11.2 24 1.2 160 56 126/80
4mths neg 22 neg 6 4.94 24.1 22.66 1.1 9.4 12th day 22 0.8 154 58 112/70
3mths neg 30 neg 6 5.89 45.4 58 1.4 10 9th day 20 1 155 59 120/70
6mths neg 40 neg 7 4.76 11.3 208 1.5 9.2 post 28 1.2 153 60 130/80
5mths neg 22 pos 128 7 5.74 43.2 51 0.9 13.2 24 1.2 171 65 130/80
6mths neg 45 pos 32 7 6.82 79 17.15 1.3 8.6 post 29 1.1 168 65 130/80
8mths pos 33 pos 128 10 5.2 32.5 243.36 1.2 9.3 8th day 31 0.5 150 53 120/80
4mths pos 50 pos 128 8 5.98 58.2 21.67 2.6 10.4 post 13 1.1 154 49 130/80
2mths pos 52 pos 16 7 5.54 15.2 1.099 1.3 10.4 21st day 19 0.7 149 50 120/80
6mths pos 18 neg 7 4.25 17.8 3.18 1.9 11 hystrectomy 27 0.6 152 55 120/70
5mths pos 35 neg 7 6 57.6 103.33 1.5 9.6 4th day 12 0.9 164 55 110/70
6mths pos 35 pos 64 10 4.54 17.4 15.75 4.2 9.8 7th day 22 0.7 156 56.5 120/70
2 mths neg 40 pos 64 7 5.35 44.8 36.78 1.3 9.7 24th day 19 1 153 60 130/80
6mths pos 40 pos 64 10 5.46 88 211.5 3.4 10.4 18thday 28 1.1 160 49 110/70
2mths pos 35 pos 256 8 5.96 36 2.14 1.3 9.5 15th day 25 0.6 150 57.5 130/80
7mths pos 45 pos 16 10 6.73 11.7 139 1.1 10.7 post 20 1 151 59 120/80
3mths pos 50 pos 256 10 4.59 15.7 14.75 1.5 10.5 post 31 1.2 148 52 122/70
6mths neg 11 pos 64 6 4.62 48.5 113.8 0.9 9.8 post 25 0.9 156 63 130/80
6mths pos 20 pos 128 8 4.67 36.8 40 1.3 9.3 22nd day 22 0.7 162 57 120/80
9mths pos 35 pos 64 7 4.92 14.6 6 1.5 9.2 post 21 0.8 149 55 120/80
5mths pos 56 pos 128 10 6.37 70.5 9 2.1 10.5 21st day 25 0.5 153 58 130/80
6mths pos 25 pos 128 10 5.76 25.6 1.72 1.3 10.2 12th day 26 0.8 149 57 120/70
3mths pos 20 neg 7 5.07 30.5 71.4 5.4 10.3 post 28 0.7 145 59 122/70
6mths pos 95 pos 64.4 7 5.5 37.4 22.65 1.4 10.9 post 27 0.8 160 56 130/80
6mths pos 32 neg 7 5.3 22.7 9.1 1.2 9.8 2nd day 29 1 156 60 120/80
2mths pos 36 neg 6 4.56 29.4 22.5 1.3 11 8th day 17 0.5 149 54 130/80
3mths pos 40 neg 6 5.08 27.1 1.2 2 10.5 11th day 30 0.8 161 63 120/80
6mths neg 10 neg 6 3.8 29.9 29.26 1.2 10.4 post 26 0.7 150 60 120/80
6mths pos 32 neg 10 5.99 76.7 0.81 2.3 9.8 24th day 19 0.5 154 49 120/80
7 mths neg 38 neg 6 5.42 44.2 1.43 1.1 11.2 post 26 0.9 148 60 120/80
s.no name age sex rf crp esr TSH µIU/ml anti ccp prl hb menstruation ureamg/dL creatininemg/dL ht cm wt kg BPmmofHg
1 shakila 56 f neg neg 12 0.9 4.57 1.6 11 post,10yrs 24 1 153 53 130/80
2 priya 39 f neg neg 10 1.3 3.02 10.2 11.2 23 0.6 167 72 120/70
3 faridha 38 f neg neg 8 1.2 2.05 20.1 10.6 21stday 22 0.8 155 62 110/70
4 kanan 30 m neg neg 12 2.2 16.33 10.7 13 26 1 164 60 120/70
5 viji 25 f neg neg 10 1.5 1.8 15 9.8 27thday 18 0.5 150 59 110/70
6 jaya 29 f neg neg 12 5.1 2.5 17.5 10.2 25th day 21 0.8 154 60 120/70
7 jerisah 25 f neg neg 8 1.3 9.32 15.9 10 15th day 19 0.5 150 53 110/70
8 ravindran 24 m neg neg 6 1.9 2.4 17.2 13.2 22 0.8 168 55 120/70
9 suseela 25 f neg neg 8 2.9 5 15.2 10.4 3rd day 24 0.8 160 64 122/70
10 raja 53 m neg neg 12 1.7 4.4 17.3 12.8 26 1.3 165 75 110/70
11 usha 32 f neg neg 8 3.3 5.6 19.1 12 23rd day 20 1 154 64 130/80
12 kajalakshmi 57 f neg neg 10 1.3 5.9 7.5 10 post 27 1.1 156 70 130/80
13 bhavani 41 f neg neg 10 2.8 5.2 16 11.8 12th day 24 0.8 160 71 120/70
14 revathi 56 f neg neg 10 2.5 1.6 5 12.4 post,16yrs 25 0.7 150 52 130/80
15 karthiga 28 f neg neg 12 3.1 0.8 19.8 12.8 18th day 21 0.6 150 56 120/80
16 amirtha 34 f neg neg 8 2.8 11.2 19.2 13 11th day 25 0.9 162 72 130/80
17 tamilselvi 52 f neg neg 12 4.3 1.45 6 10.8 post,8yrs 27 1 160 75 110/70
18 nirmaiadevi 35 f neg neg 8 1.9 11.4 20.5 13.2 22nd day 28 1.1 160 76 130/80
19 jaya 42 f neg neg 22 3.6 9.8 14.6 10.4 15th day 22 0.6 161 57 120/80
20 lalitha 65 f neg neg 22 1.3 2.4 4.5 9.2 post 27 1 156 57 110/70
21 vijayakumari 45 f neg neg 12 1.2 2.4 20.8 11.2 24th day 26 1 149 54 120/70
22 govindarajan 67 m neg neg 20 1.9 4.8 19.2 12 24 1.3 167 64 130/70
23 rani 30 f neg neg 22 3.9 1.36 6.6 12.2 12th day 22 1.2 157 54 120/70
24 rabiya 32 f neg neg 12 4.2 12.18 16.4 10.8 8th day 26 1 171 70 120/80
25 jayasudha 31 f neg neg 12 2.4 2.6 21.1 12.1 14thday 23 0.7 153 58 130/80
26 kausalya 37 f neg neg 16 2.1 6.8 21.1 9.4 16thday 25 0.8 156 50 120/80
27 pushparani 52 f neg neg 12 3.2 6.4 10.8 11.2 post 26 0.5 158 51 120/80
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RESULTS 
Table 1  Distribution of study population based on Gender 
 
GENDER CASES CONTROLS TOTAL 
MALE 7(12.7%) 4(14.8%) 11(13.4%) 
FEMALE 48(87.3%) 23(85.2%) 71(86.6%) 
TOTAL 55 27 82 
 
Table 1 shows the number of males and females in the study population. This 
table reveals that majority of the study population is females, which implies study is 
skewed towards females. 
Table 2  Distribution of females in study based on menstrual phase. 
 
Phase of Menstruation CASES CONTROLS 
Bleeding Phase 4(8.3%) 2(8.7%) 
Follicular Phase 15(31.3%) 6(26.1%) 
Luteal Phase 10(20.8%) 6(26.1%) 
Post menopause 19(39.6%) 9(39.1%) 
TOTAL 48 23 
 
Table 2 shows the number of females in each phase of menstrual cycle and 
the postmenopausal women. Among the premenstrual population, contribution by 
females in follicular phase was more when compared with luteal phase and bleeding 
phase. 
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Table 3   Distribution of age in the study group 
 
AGE in years CASES CONTROLS 
21-30 10 (18.2%) 8 (29.6%) 
31-40 18 (32.7%) 8 (29.6%) 
41-50 14 (25.4%) 3 (11.2%) 
51-60 10 (18.2%) 6 (22.2%) 
>60 3 (5.5%) 2 (7.4%) 
Total 55 27 
 
Table 3 shows that major study population belongs to the age group of 31 to 40 
years. 
Table 4 –Comparison of Serum Prolactin concentration between cases and 
control in both males and females. 
Variable Group N Mean  Std. Dev SE Mean t-Value P-Value 
Prolactin 
in ng/mL 
Cases 55 33.531 17.9264 2.4172 
7.161 
<0.001 
S Control 27 14.404 5.9063 1.1367 
S- significant 
Serum Prolactin concentration between cases and controls was compared 
using unpaired students’ t- test. The mean Serum Prolactin concentration in cases 
was 33.531±17.92 ng/mL. The mean Serum Prolactin concentration in controls was 
14.4±5.9 ng/mL. The standard error of mean for cases was 2.42. The standard error 
of mean for controls was 1.14. The 95% confidence interval for mean of serum 
Prolactin concentration in cases was 50.84 to 16.22 ng/mL. The 95% confidence 
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interval for mean of serum Prolactin concentration in controls was 22.54 to 6.26 
ng/mL. The p value obtained was less than 0.001. It was statistically highly 
significant. 
Figure 1  Mean Prolactin concentration between cases and controls in both 
males and females. 
 
Figure1 shows the mean Prolactin concentration in cases and controls in both 
sexes.The Serum Prolactin concentration in cases was higher than controls. It is 
statistically significant.   
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Table 5 Comparison of Serum Prolactin concentration between cases and 
controls among females. 
Group Number 
Mean 
PRL 
ng/mL 
Std Dev SE mean t-value p-value 
cases 48 33.88 18.75 2.7 
4.9174 
<0.0001 
S controls 23 14.11 7.9 3 
S - significant 
Serum Prolactin concentration between cases and controls among females 
was compared using unpaired students’ t- test . The mean Prolactin concentration in 
female RA patients was 33.88±18.75 ng/mL. The mean Prolactin concentration in 
female controls was 14.11±7.9ng/mL. The difference in mean between the two 
groups was statistically highly significant with the p value  <0.0001. 
Figure 2- Mean serum Prolactin concentration in female Rheumatoid Arthritis 
patients and female controls 
 
Figure 2 shows the Serum Prolactin concentration in cases and controls 
among the females in this study group. Serum Prolactin concentration in female RA 
patients was higher than healthy  female controls and it was statistically significant.  
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Table 6 Comparison of Serum Prolactin concentration between cases and 
controls among males 
Group Number Mean PRLng/mL Std dev 
SE 
mean 
t-value p-value 
cases 7 31.16 7.9 3 
3.581 0.0059(S) 
controls 4 16.1 3.2 1.6 
 S - significant 
Table6 shows the comparison of mean Serum Prolactin concentration 
between male RA patients and healthy male controls. The mean Prolactin 
concentration in male RA patients was 31.16±7.9ng/mL. The mean Prolactin 
concentration in male controls was 16.1±3.2 ng/mL. The Serum Prolactin 
concentration in both these groups was compared using unpaired students’ t-test . 
The difference in mean between the groups was statistically significant  with the  p 
value- 0.0059. 
Figure 3  mean serum Prolactin concentration in male RA patients and 
apparently healthy male controls. 
 
    Figure3 shows that Serum Prolactin concentration in male RA patients was higher 
than apparently healthy male controls. The difference was statistically significant. 
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Table 7 Mean Serum Prolactin concentration in females in different phases of 
the menstrual cycle in both cases and controls. 
Group Menstruation 
phase 
Follicular 
phase 
Luteal 
phase 
Post 
menopausal 
Cases 33.7(n=4) 30(n=15) 46.1(n=10) 30.56(n=19) 
Controls 10.9(n=2) 17.63(n=6) 18.13(n=6) 9.8(n=9) 
 
Table7 shows the mean prolactin concentration in females in various phases 
of menstrual cycle . The Prolactin concentration in Luteal phase was higher in both 
cases and controls . The Serum Prolactin concentration was higher in cases when 
compared to controls in all the three phases in premenopausal women. The Serum 
Prolactin concentration was higher  in postmenopausal  RA patients than the 
corresponding controls. 
Table 8 Mean serum Prolactin concentration & DAS28(3)  in both males and 
female Rheumatoid Arthritis patients. 
Group number Mean DAS28(3) 
score 
Mean PRL in 
ng/mL 
Moderate activity 22 4.4 25.03 
High activity 33 6 39.2 
 
Table 8 shows the mean DAS score and Serum Prolactin concentration in 
RA patients with moderate and high disease activity. Among cases 22 had moderate 
disease activity score with a mean DAS score of 4.4±0.4 and mean serum PRL 
concentration was 25.03±10.3ng/mL in those patients. Among cases 33 individuals 
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had high disease activity score . The mean disease activity score was 6±0.7 and 
mean serum PRL concentration was 39.2±19.4ng/mL. 
Figure 4 Disease activity in cases based on DAS28(3) in cases. 
 
Figure 4 shows among cases 40%(n=22) had moderate disease activity . The 
DAS score of these individuals varies from 3.2 to 5.1. Among cases 60%(n=33) had 
high disease activity . The DAS score of these individuals was more than 5.1 
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Table 9 Comparison of mean Serum Prolactin concentration between moderate 
and high disease activity RA patients in both males and females. 
Group number 
Mean PRL 
ng/mL 
t-value p-value 
Moderate 
activity 
22 25.03±10.3 
3.14 0.0028(S) 
High activity 33 39.2±19.4 
S- significant 
The comparison of mean Serum Prolactin concentration between RA patients 
with moderate and high disease activity score was done using unpaired students’ t-
test. The difference in mean between the 2 groups was statistically highly significant 
with a pvalue- 0.0028. 
Figure 5 Mean Serum Prolactin concentration in RA patients with moderate 
disease activity and high disease activity in both males and females. 
 
Figure 5 shows the mean serum Prolactin concentration in RA patients with 
moderate disease activity score and high disease activity score. Mean serum 
Prolactin concentration in RA patients with high disease activity score was higher 
than in RA patients with moderate disease activity score. 
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Table 10 Mean Serum Prolactin concentration in RA patients in association 
with duration of joint symptoms. 
Symptom duration in months Number Mean PRL in ng/mL 
≤2 months 10 27.45±9.7 
3 – 6 months 36 35.86±19.87 
>6 momths 9 31±13.2 
 
Table 10 shows the mean Serum Prolactin concentration in RA patients in 
relation to the duration of joint symptoms.Most of the study population had 
presented after 2 months of onset of symptoms. 
Table 11 Comparison of mean Anti CCP between cases and controls 
Group Number 
MeanAnti CCP in 
U/L 
p-value 
cases 55 47.5±64.8 0.0012 
S controls 27 5.3±3.9 
S- significant 
Table 11 shows the mean Anti CCP levels in cases and controls.The Anti 
CCP in RA patients was higher than controls. The difference in mean of Anti CCP 
between cases and control was analysed using unpaired students’ t –test and the 
difference in mean was statistically significant with a p value 0.0012. 
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Figure 6 Anti CCP status among RA patients in the study group 
 
Figure 6 shows the percentage of Anti CCP positivity and Anti CCP negative 
individuals among the cases. Approximately 50% ie 46%(<20U/L) of RA patients 
were Anti CCP negative. Among the positive individuals majority were 
27% - weak positive (20 – 39.9 U/L).  
22% - strong positive (≥60U/L) 
5% - positive(40-59.9 U/L). 
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Table 12  Mean Serum Prolactin Concentration in Anti CCP positive and Anti 
CCP negative individuals among cases and Mean Anti CCP in each groups 
Group Number Mean PRL ng/mL 
Mean Anti CCP 
U/mL 
Weak positive 
 (20 -39.9 U/L) 
15 36.67±10.24 25.8±4.75 
Positive 
 (40-59.9 U/L) 
3 41.8±3.7 49.7±7.4 
Strong positive 
(≥60 U/L) 
12 34±21 158.86±51.87 
Negative 
(<20U/L) 
25 30.45±19.9 6.75±5.2 
 
Table 12 shows the mean serum Prolactin concentration in Anti CCP 
positive and Anti CCP negative individuals. The mean serum PRL in Anti CCP 
negative RA patients was lower than the positive individuals. In the Anti CCP 
positive(40 to 59.9U/L) RA patients  Serum Prolactin was higher than strong 
positive, weak positive and negative patients. 
The mean Anti CCP in Weak positive patients was 25.8±4.75 U/L . 
 The mean Anti CCP in Positive Patients was 49.7±7.4U/L. 
 The mean Anti CCP in Strong positive individuals was 158.86±51.87U/L. 
 The mean Anti CCP in negative RA patients was 6.75±5.2 U/L. 
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Figure 7 Mean Serum Prolactin Concentration in Anti CCP positive Patients. 
 
 
Figure 7 shows the mean Serum Prolactin concentration in weak positive , positive , 
strong positive Anti CCP RA patients. The mean  serum Prolactin 
concentration(41.8 ng/mL)  was higher in the positive group. The mean Serum 
Prolactin Concentration in the strong positive group was lower than both positive 
and weak positive Rheumatoid Arthritis patients. 
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Table 13 Comparison of mean serum Prolactin concentration between Anti 
CCP positive and Anti CCP negative individuals. 
Group number Mean PRL ng/mL p- value 
AntiCCP positive 30 36.5±15.3 0.2394 
NS AntiCCP negative 25 30.5±19.9 
NS- Not significant 
Table 13 shows the comparison of mean Serum Prolactin concentration 
between Anti CCP positive and negative individuals. The mean between the two 
groups was compared using unpaired students’ t-test. The difference in mean 
between the two groups was not significant statistically; p value-0.2394. 
Figure 8 Mean Serum Prolactin concentration in Anti CCP positive and Anti 
CCP negative RA patients. 
 
Figure 8 shows the mean Serum PRL concentration between the Anti CCP positive 
and negative individuals.The serum Prolactin concentration in Anti CCP positive 
RA patients was higher but the difference was not statistically significant. 
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Figure 9 Rheumatoid Factor positivity in the cases 
 
 
 
Figure 9 shows the percentage of Rheumatoid factor positive and 
Rheumatoid factor negative individuals among the cases. Majority of the cases was 
RF negative  58%. 42% of the cases were RF positive.  
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Table 14 Comparision of mean Serum Prolactin concentration between RF 
positive and RF negative RA patients 
 
Group Number Mean PRL ng/mL p- value 
RF positive 23 36.58±21.6 0.266 
NS RF negative 32 31.13±14.35 
NS- not significant 
Table 14 shows the comparison  of Serum Prolactin concentration between 
RF positive and RF negative patients. The mean between the two groups was 
compared using unpaired students’ t test. The difference in meanserum PRL 
between the RF positive and RF negative groups was statistically not significant. 
Figure 10 Mean Serum PRL concentration in RF positive & RF negative RA 
patients. 
 
 
Figure 10 shows the mean serum PRL concentration in RF positive & RF 
negative individuals. The serum Prolactin in RF positive cases was 36.58ng/mL ;it 
was higher than the RF negative patients but the difference in mean was statistically 
not significant; p-value-0.266. 
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Figure 11 Antibody status among Rheumatoid Arthritis patients. 
 
Figure 11 shows the percentage distribution of cases with respect to both RF  and 
Anti CCP. In the cases 24% were positive for both RF & Anti CCP. 27% of cases 
were negative for both RF & Anti CCP.31% of cases were positive for Anti CCP 
alone. 18 % of cases were positive for RF alone. Hence majority of the cases were 
positive for Anti CCP alone.  
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Table 15 Comparison of mean serum PRL concentration between 4 groups( 
RF& Anti CCP +ve , RF+ve AntiCCP –ve , RF-ve Anti CCP +ve,RF&Anti 
CCP negative) 
  Table 15a Oneway ANOVA to compare mean values between groups. 
 
Variable Groups N Mean Std. Dev P-Value 
PRL 
ng/mL 
Both RF & Anti CCP 
positive 13 38.654 19.6836 
0.448 
Only RF positive, Anti CCP 
negative 10 34.540 24.9064 
Only Anti CCP positive,RF 
negative 17 34.141 11.7759 
Both RF & Anti CCP 
negative 15 27.687 16.8622 
Total 55 33.520 17.8998 
 
Table 15b ANOVA Table 
Variable Sum of Squares df Mean Square F-Value P-Value 
PRL 
Between 
Groups 870.013 3 290.004 
0.900 
0.448 
NS Within Groups 16431.675 51 322.190 
Total 17301.688 54  
NS- not significant 
Table 15 shows ANOVA was used to compare the mean serum Prolactin 
concentration between the  4 groups. The mean serum Prolactin concentration was 
higher in RA patients with both RF and Anti CCP positive than the other 3 groups 
viz, RF alone positive, Anti CCP alone positive and both Anti CCP & RF negative. 
But the difference in mean was not statistically significant ; p value- 0.448. 
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Table 16 Comparison of mean serum Prolactin concentration between Both RF 
& Anti CCP positive and both RF & Anti CCP negative RA patients. 
Group Number Mean ng/mL p- value 
RF& Anti CCP +ve 13 38.654±19.6836 0.1242 
NS RF & Anti CCP -ve 15 27.687±16.8622 
  NS – Not Significant. 
Using Unpaired students’ t test the difference in mean serum PRL 
concentration between RF & Anti CCP positive and RF& Anti CCP negative groups 
was found to be statistically not significant; p-value – 0.1242. 
Figure 12 mean serum PRL levels with respect to antibody status of RA patients. 
 
Figure 12 shows the mean serum PRL concentration with respect to their antibody 
status. The concentration of serum Prolactin was highest (38.65ng/mL) in RA 
patients with both antibodies RF & Anti CCP positive, lowest (27.7 ng/mL) in RA 
patients with both the antibodies negative. The mean serum concentration in RA 
patients with RF positivity alone was 34.54ng/mL . The  mean concentration in Anti 
CCP alone positive RA patients was 34.14ng/mL. The mean prolactin concentration 
in  RA patients with either RF or Anti CCP positive was almost the same . 
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Table 17 Mean DAS 28(3) with respect to antibody status 
Group Number Mean DAS28(3) score 
Both RF& Anti CCP +ve 13 5.5±1.1 
RF alone positive 10 5.6±0.8 
Anti CCP alone positive 17 5.1±0.97 
Both RF&Anti CCP -ve 15 5.3±0.93 
  
Table 17 shows the mean disease activity score in RA patients with respect to their 
antibody status( RF & Anti CCP). It was almost similar in all the 4 groups. 
Table 18 comparison of mean ESR between cases and controls. 
Group Number Mean  mm at the end of 1 hour p- value 
Cases 55 38.6±27.1  
<0.0001(Significant) 
Controls 27 12.1±4.4 
 
Comparison of ESR between cases and controls was done using Unpaired 
students’ t –test the difference in mean of ESR between cases and controls was 
statistically significant p-value <0.0001 
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Table 19 Comparison of mean ESR between RA patients with moderate & high 
disease activity scores. 
Group Number 
Mean ESR mm at the 
end of 1 hour 
p- value 
Moderate DAS 
(3.2-5.1) 
22 23.36±11.9 0.0004 
Significant 
High DAS(>5.1) 33 48.76±29.56 
 
The ESR was high in RA patients with high disease activity score. 
Comparison of mean ESR between RA patients with moderate and high disease 
activity score was done using unpaired students’ t test. The difference in mean 
between the two groups was statistically significant; p value  0.0004.  
Table 20 Correlation between DAS score and ESR in RA patients with 
moderate and high disease activity score. 
Group Number Correlation p-value 
Moderate DAS 22 0.4545 0.033 
High DAS 33 0.594 0.0003 
 
Table 20 shows the correlation between ESR and DAS28(3) score in both moderate 
and high disease activity scores in RA patients. Pearsons correlation coefficient was 
used to find the association between disease activity score and ESR. A moderate 
positive linear correlation exists between DAS and ESR in RA patients with 
moderate disease activity r value  0.4545 and it was statistically significant ;p-value 
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0.033. A moderate linear positive  correlation exists between DAS and ESR in RA 
patients with high disease activity r value 0.594 and this is statistically highly 
significant p value 0.0003. 
Table 21 Correlation between ESR and Serum PRL in RA patients with 
moderate and high disease activity. 
Group Number correlation p-value 
Moderate DAS 22 -0.3737 0.087 
High DAS 33 0.1331 0.46 
  
Table 21 shows the correlation between ESR and serum PRL concentration 
in RA patients with moderate and high disease activity.Pearson correlation 
coefficient for ESR and serum PRL concentration in RA patients with moderate 
DAS was -0.3737,fair negative linear correlation but statistically not significant. 
Pearson correlation coefficient for ESR and serum PRL concentration in RA patients 
with high DAS was 0.1331, weak positive linear correlation and statistically not 
significant. 
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Table 22 Correlation between DAS score and serum PRL in RA patients with 
moderate and high DAS scores. 
Group Number Correlation p-value 
Moderate DAS 22 -0.133 0.55 
High DAS 33 0.102 0.57 
  
Table 22 showing correlation between DAS28(3) scores & serum PRL concentration 
in RA patients. Pearson correlation coefficient between DAS score and Serum PRL 
concentration in RA patients with moderate disease activity scores was -0.133,a 
weak negative linear  correlation and statistically not significant. Pearson correlation 
coefficient between DAS score and Serum PRL concentration in RA patients with 
high disease activity scores was 0.102 , a weak positive linear correlation and 
statistically not significant. 
Table 23 Correlation of Serum prolactin concentration with DAS28(3) score in 
RA patients 
DAS 
Correlation 0.345 
P-Value 0.010 
N 55 
 
Table 23 shows the  Correlation of Serum Prolactin concentration with 
DAS28(3) score in RA patients .The  Pearson correlation coefficient between DAS 
score and Serum PRL concentration in RA patients was 0.345. It was a fair positive 
linear correlation and it was statistically significant; p value 0.01. 
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Figure 13 Correlation between Serum PRL conc & DAS 
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Table 24 Pearson Correlations between prolactin and  variables other than 
DAS among cases 
 
S.NO Variables Prolactin 
1 
Anti CCP 
Correlation 0.042 
P-Value 0.760 
N 55 
2 
ESR 
Correlation 0.236 
P-Value 0.082 
N 55 
3 
RF values in RF positive 
patients 
Correlation 0.089 
P-Value 0.681 
N 24 
4 
ACR score 
Correlation 0.247 
P-Value 0.070 
N 55 
5 
Symptom Duration 
(months) 
Correlation 0.088 
P-Value 0.521 
N 55 
6 
Age (years) 
Correlation -0.118 
P-Value 0.392 
N 55 
 
Table 24 shows the correlation of Serum PRL concentration with variables 
like Anti CCP, ESR, RF, ACR score, symptom duration, Age . The Correlation was 
found using Pearson correlation coefficient . NO correlation exists between Anti 
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CCP, RF, Symptom duration , Age with Serum Prolactin concentration. A fair 
correlation exists between ESR, ACR score with Serum Prolactin concentration but 
they were not statistically significant. 
Table 25 Comparison of mean serum Prolactin concentration in CRP positive 
and CRP negative  RA patients. 
Group number Mean ng/mL p-value 
CRP positive 39 (70.9%) 33.88±17.83 0.8281 
Not Significant CRP negative 16(29.1%) 32.73±17.56 
 
Table 25 shows the comparison of mean serum Prolactin concentration in 
CRP positive and CRP negative  RA patients. Among the cases 70.9% were positive 
for CRP. The mean serum PRL concentration in both these groups are almost 
similar. The difference in mean between the two groups was calculated using 
unpaired students’ t- test and it was not statistically significant. 
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Table 26 shows the characteristics of study subjects. 
S.NO VARIABLES CASES CONTROLS P- VALUE 
1 AGE in years 41.5±11.6 40±12.7 0.595 
2 AGE OF MALES in 
years 
36.14±11.68 43.5±17.36 0.418 
3 AGE OF FEMALES in 
years 
42.29±11.37 40.65±11.32 0.571 
4 SERUM UREAin 
mg/dL 
24.56±4.7 23.8±2.6 0.437 
5 SERUM 
CREATININE in 
mg/dL 
0.9±0.2 0.8±0.2 0.036 
6 SERUM TSH in 
µIU/mL 
2.5±2.2 2.4±1.1 0.82 
7 ESR in mm at the end 
of 1hr 
38.6±27.1 12.1±4.4 < 0.0001 
8 Anti CCP in U/mL 47.5±64.8 5.3±3.9 0.0012 
9 SERUM PROLACTIN 
in ng/mL 
33.53±17.9 14.4±5.9 < 0.001 
 
<0.05 – Significant 
<0.01 – Highly Significant 
>0.05 – Not Significant 
DISCUSSION 
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DISCUSSION 
Rheumatoid Arthritis , a chronic inflammatory Autoimmune disease 
affecting joint synovium , cartilage ,bursae  causes functional disability. This disease 
present world wide occurs by an interplay of immunological , inflammatory , genetic 
and  environmental  genetic factors. However autoimmunity plays a pivotal role in 
its pathogenesis.1 
The immune balance is maintained by cytokines released by Th1 and Th2 
lymphocytes.  Break in immunetolerance or immunedysregulation or cytokine 
imbalance provokes a autoimmune response. The tissue damage in autoimmune 
diseases occurs by type III hypersensitivity reactions, damage is caused by immune 
complex deposition activating classical complement pathway 7. The pathogenesis 
has been explained in detail in the review of literature. 
Prolactin known as a lactogenic hormone is a cytokine .In addition to 
secretion from acidophills of anterior pituitary it is also secreted by lymphocytes, 
decidua of uterus, amnion, chorion of placenta, mammary gland and many regions 
of brain 42. The role of Prolactin in immune regulation and autoimmune diseases had 
been explained by many invitro and invivo animal and human studies. 
Prolactin  
• regulates the maturation of CD4- and CD8- cells   CD4+ and CD8+ cells.69  
• decreases  or prevent the apoptosis of lymphocytes.75 
• Interferes with peripheral tolerance of B cells. 92 
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• enhances the proliferative response to  certain antigens and mitogens.83 
• upregulates the expression of Th1 cytokines Th1 cytokines are involved in 
autoimmune diseases.84 
Prolactin  role in immuneregulation and autoimmune response has been 
suggested by the above said facts. 
Hyperprolactinemia due to various etiologies have been associated with 
increased incidence of auto antibodies in serum like Anti-Ro , Anti- thyroid , Anti- 
cardiolipin , Anti- dsDNA , Antinuclear antibodies in individuals without clinical 
evidences of autoimmune diseases 137,165,167. Also serum Prolactin is elevated in 
patients with SLE,RA, Psoariasis,Multiple sclerosis,Reiter syndrome, Uveitis , 
Sojgren syndrome 2,166-169. Elevated Prolactin  was seen in cardiac allograft 
transplant rejection patients and in mice with skin allograft rejection 158. These facts 
suggest that Certain case reports show that administration of Bromocryptine , 
cabergoline in Rheumatoid Arthritis  patients with elevated serum Prolactin cause 
disease remission 159-163. But these evidences were not consistent . Hence the present 
study was carried out to determine the status of serum Prolactin in patients with 
recently diagnosed Rheumatoid arthritis.  
In this study 55 recently diagnosed patients with Rheumatoid Arthriti s were 
recruited from the Rheumatology Out Patient department of Rajiv Gandhi 
Govt.General Hospital Chennai .The diagnosis of RA was based on 2010 American 
College of Rheumatology criteria170 . These patients were not under any treatment. 
Both Rheumatoid factor positive and RF negative RA patients were included in the 
study. 27 age and sex matched apparently healthy volunteers who had no clinical 
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evidence of Rheumatoid Arthritis were selected. Serum urea. Serum Creatinine ,  
Serum TSH , Rheumatoid Factor,  ESR , CRP , serum Prolactin and serum Anti 
CCP were determined in all the 55 RA patients and 27 controls.Disease activity was 
assessed using DAS28(3) score 164 in all the 55 patients. 
The cases and control group had been matched with respect to age, sex , 
serum urea, creatinine, TSH as shown by p value less than 0.05  
Among the cases 87.3% ( 48 out of 55) were females which matches with the 
literature that autoimmune diseases are common in women 61. The onset of 
Rheumatoid Arthritis among the cases in this study was between 30 to 40 years of 
age which again matches with the literature where it is mentioned that 80% of 
patients develop the disease between 35 and 50 years of age 1. The incidence is more 
common in women older than 60 years of age 1. In this study the predominant age 
group is 31 to 40 years of age. Since only recently diagnosed RA patients and not 
under any treatment were included , the major contribution is by patients in 31 to 40 
years of age. In this study premenopausal women were more than postmenopausal 
women this coincides with the literature 1.  
Only 18%  (n=10) of cases had presented within 3 months of onset of 
symptoms Majority of patients 65%(n=36) presented 3 to 6 months of onset of 
symptoms. 
 42 %(n=23) of patients with RA were positive for RF & 58%(n=32) were 
negative for Rheumatoid factor. Although Rheumatoid Factor is not specific for 
Rheumatoid Arthritis, RF positivity is a cardinal feature of RA.  It is mentioned that 
seroconversion in RF negative patients may occur during the first year of disease 
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activity, hence these Seronegative RA patients in the present study might turn 
seropositive for RF later.  
Among  cases 31%(17) of the patients were positive for Anti CCP antibody 
alone, 23.6 %(13) were positive for both RF and Anti –CCP antibodies. Anti CCP is 
90% specific for Rheumatoid arthritis1. 18.2%(10) of cases were positive for RF 
alone.27.3% (15) were negative for both the antibodies.. According to 2010 
ACR/EULAR criteria  ,‟In a patient with classical features of Rheumatoid arthritis 
namely morning stiffness for more than 1 hour for atleast 6 weeks, involvement of 
two or more small joints, RF and anti –CCP antibodies does not exclude the 
diagnosis of Rheumatoid Arthritis” 170. 
 ESR was elevated in 49 (89.1%) patients and was within normal limits for 6 
patients.  
CRP was positive for 70.9% of patients. 
60%(33) of the RA patients had a high disease activity score (>5.1). 40%(22) 
had a moderate disease activity score (3.2-5.1).  
In this study the mean PRL concentration among the cases (n=55) was 
33.53±17.93 ng / mL which was significantly higher than the control group (n=27) 
where it was 14.4±5.9ng/mL with p value of <0.001 which correlates with that 
available in literature 
 The mean serum PRL concentration in female patients(n=48) was 
33.83±18.75ng/mL and was higher than female individuals in the control(n=23) 
group (14.11±7.9 ng/mL) which is statistically highly significant (p value <0.0001). 
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Similarly the mean serum PRL concentration in male(n=7) patients  
(31.16 ±7.9 ng/mL) was higher than male individuals in the contro(n=4)l group  
(16.1±3.2 ng/mL); which is statistically highly significant (p value 0.0059). All these 
results correlate with the findings in the literature.171-180 
The concentration of Serum Prolactin was higher in patients who presented 
between 3 and 6 months of joint symptoms (35.86±19.9ng/mL ) than patients who 
presented earlier i.e. within 3 months of joint symptoms (27.45±9.7ng/mL ) or later 
than 6 months ( 31±13.2 ng/mL). However in those patients who presented earlier 
had higher serum PRL concentration compared to the control group  (27.45ng/mL in 
early presentation as against 14.4ng/mL in the control group) 
Although the mean serum PRL concentration in  RF negative & Anti –CCP 
antibodies negative  patients was lower (30.45±19.9ng/mL,n=25 ) than in those 
patients who were positive for both(36.1±15.3,n=35), it was not statistically 
significant ( p value-0.2394)   
An ANOVA comparison of mean PRL concentration between the 4 groups, 
RF& Anti CCP positive , only RF positive, only Anti CCP positive , both RF & Anti 
CCP negative did not reveal any statistically significant difference in serum PRL 
concentration  
From the above discussion it can be inferred that serum PRL concentration is 
higher in patients with RA, which is one of the aim of this study However it did not 
correlate with other markers of RA namely RF & Anti CCP antibodies positivity   
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Discussing the second aim of the study correlating serum PRL concentration 
with  disease activity as assessed by DAS 283 score164, it is seen that the mean 
serum PRL concentration is higher in patients and a Pearson’s correlation coefficient 
showed a fair correlation with a r value of 0.345 & p-value of 0.01.This correlates 
with studies in literature 177,179. 
The Serum PRL concentration did not correlate with ESR,ACR score, 
Concentration of Anti CCP antibodies, Symptom duration in RA patients in this 
study. 
 Hyperprolactenemia in patients with RA is not likely be due to macroprolact 
in as the predominant antibody in RA is of IgM class which might not bind with 
Prolactin 1. Macro prolactin is a complex of Prolactin with IgG whose renal 
clearance is slow and hence the hyperprolactinemia . In this study 70.9% of patients 
were hyperprolatinemic. Hence elevated serum Prolactin in this study is not likey to 
be due to macroprolactin. Some studies stands as an evidence for this 181,182.    
 
 
LIMITATION OF THE 
STUDY 
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LIMITATIONS OF THE STUDY 
 
1. The number of males  in the study group was low and the study is more 
skewed towards female population . 
2. Juvenile Rheumatoid arthritis patients were not included in the study. 
3.  Screening for Macroprolactin was not done as elevated serum PRL levels in 
patients and controls could have been due to macroprolctin  
4. Pulsality of prolactin secretion was not  taken in to account as PRL secretion 
is pulsatile . 
SUMMARY 
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SUMMARY 
  The role of  Prolactin in autoimmune diseases & use of anti Prolactin drugs  
in disease remission has been described & investigated in several studies. The role 
of anti- prolactin drugs  in remission of disease activity have been investigated.  The 
present study was carried out to correlate serum Prolactin levels with disease activity 
in recently diagnosed Rheumatoid Arthritis patients. 
 A case-control study was carried out in  55 recently diagnosed untreated 
Rheumatoid factor positive & RF negative  Rheumatoid Arthritis patients and 27 age 
& sex matched apparently healthy individuals. The diagnosis of RA was made using  
ACR criteria 2010.  Serum Prolactin(ELISA) ,Anti CCP(ELISA) , RF (Latex 
agglutination method) , TSH(ELISA),ESR(Westergrens method),Serum urea & 
creatinine were assayed.  Disease severity was assessed by DAS(28) formula. 
Statistical evaluation was done  byunpaired students’ t-test ,Pearson correlation co-
efficient,ANOVA   
Serum Prolactin levels in RA patients was significantly higher (33.53±17.9 
ng/mL) compoared to controls (14.4±5.9) with p value of < 0.001 . A fair correlation 
was found between disease activity and serum Prolactin levels ( r = 0.345 ; p = 
0.01).  
Elevated levels of serum prolactin indicates the immunomodulatory role of 
PRL and its relationship to diseases activity. Use of Anti Prolactin drugs may be of 
use in  patients with hyperprolactinemia. 
 
CONCLUSION 
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CONCLUSION 
Rheumatoid Arthritis is an autoimmune disease.  The role of Prolactin in 
immune modulation was suggested by its ability to cause T cell & B cell maturation, 
activation of T- lymphocytes by PRL in the absence of IL-2, ability to break 
peripheral tolerance. It may provoke autoimmune diseases. This study again stands 
as an evidence for Prolactin role in Rheumatoid Arthritis. The Serum Prolactin 
concentration in Rheumatoid Arthritis patients was higher than age and sex matched 
healthy individuals From this study we can infer that 
• Prolactin has a role in Autoimmune diseases. 
 
• Monitoring Serum Prolactin concentration during treatment may be of help 
since a statistically significant difference in  Serum Prolactin concentration  
was present between patients with high and moderate disease activity. 
• Including Dopamine agonist as an adjuvant in treatment of  Rheumatoid 
arthritis patients with elevated  Serum Prolactin may be of use in remission. 
 
SCOPE FOR FURTHER 
STUDIES 
111 
 
SCOPE FOR FURTHER  STUDIES 
 
i. As Serum prolactin concentrations are higher in rheumatoid arthritis 
which has both an autoimmune & inflammatory etiology  serum PRL 
concentrations could be assessed in other autoimmune diseases such 
as SLE 
ii. If Serum Prolactin concentration are measured routinely in all 
patients with RA, Dopamine agonists such as bromocryptine 
cabergoline which are inhibit PRL secretion, can be tried as an 
adjuvant  treatment especially in patients with with high serum PRL 
concentrations . 
iii. Serum Prolactin concentration can be monitored to assess disease 
progression in RA patients with elevated serum Prolactin at the time 
of presentation and compared with RA patients who had normal 
serum Prolactin  at onset . 
iv. Serum Prolactin concentration could be assessed in siblings of 
patients with Rheumatoid arthritis  and elevated serum Prolactin  
v. Serum Prolactin concentration could be correlated with inflammatory 
cytokines and HLA typing  
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©−zx¶ SÉœ™PÇ, –«ì\êuíÏ ¡i¹PÇ ©ÍË£ Cªzuzíu –¤Ô–kzvU 
ëPêÇÂ¹£ ì©³£ C•u Bªê©a]¥±−•x G•ì{ª¡£ —Ô¶ê[P°ê£ GÏ¹£ 
Aaë\¤±Ïêµ G•u –êvœ™£ HÍ–hêx GÔ–íu§£  ™«•xU ëPêsk ¡¿ 
©ÏxhÔ \£©u£ ëu«·UQÔìÈÔ. 
 GÏx –«ì\êuíÏ ¡i¹PíÂ AÉ·¤µ \ê¯•u Aí©œ™PÇ ©ÍË£ 
©−zx¶ CuÁPÃµ ë¶Ã¥k¶uÍS ¡¿ ©ÏxhÔ \£©vUQÔìÈÔ. 
 
 
Bªê©a]¤êÂ¯ íPë¤êœ–£    –[ìPÍ–êÂ¯ íPë¤êœ–£ 
       / Chx íP·ªµ ìªíP 
Ch£ :         
ìuv :  
INFORMATION SHEET 
Title : Serum Prolactin levels in Rheumatoid Arthritis Patients. 
Investigator : Dr. M. Karthiga, 
   Post Graduate, 
   Institute of Biochemistry 
   Madras Medical College, 
   Chennai – 600 003. 
 
Guide  : Dr. V.K. Ramadesikan, 
   Associate Professor, 
   Institute of Biochemistry 
   Madras Medical College, 
   Chennai – 600 003. 
 Prolactin, a hormone modulates immune response. Prolactin level is high in 
many autoimmune diseases and Rheumatoid arthritis is one of the autoimmune 
disease. Prolactin is proinflammatory in nature but also protects cartilage from 
destruction. Recent studies show that exogenous prolactin reduces disease activity. 
Knowledge regarding prolactin in rheumatoid arthritis may alter the current 
treatment or diagnostic or followup strategy. 
 Hence I am doing this study Serum Prolactin level in Rheumatoid arthritis 
patients attending Rajiv Gandhi Govt. Genral Hospital, Chennai. To do this study I 
need to collect 5 ml blood from 57 Rheumatoid arthritis patients and 24 healthy 
individuals. While collecting 5 ml of blood there will not be any side effects.  
Your identity will be confidential throughout the study and also during 
publication or presentation in any clinical forums and journals. Participation in this 
study is purely voluntary. You can withdraw from this study at any time. Your 
decision will not result in any loss of benefits to which you are otherwise entitled. 
The results of the study will be intimated to you. If you have willingness to 
participate in this study, kindly sign in this information sheet and the consent form. 
 
Signature of the Investigator :   Signature of the Participant 
       / Thumb Impression 
Place : 
Date : 
PATIENT CONSENT FORM 
Title : Serum Prolactin levels in Rheumatoid Arthritis Patients. 
Participant’s Name :   Age :   Sex:  IP / OP No. 
Address :      Project Patient No : 
 
Contact No.  : 
 The details of the study have been provided to me in writing and explaineld 
to me in my own language. 
 I confirm that I have understood the above study and had the opportunity to 
ask questions and received the information sheet. 
 I agree to use my personal clinical history and investigation details for the 
purpose of the study. 
 I agree not to restrict the use of any data or results that arise from this study 
provided such a use is only for scientific purpose(s). 
 I understand that my participation in the study is voluntary and that I am free 
to withdraw at any time, without giving any reason, without the medical care that 
will normally be provided by the hospital being affected. 
 Having understood ___________________________ S/o. 
_____________________ give my consent to participate in the study conducted by 
Dr. M. Karthiga, Post Graduate, Institute of Biochemistry, Madras Medical College, 
Chennai. 
 
Signature of the Investigator :   Signature of the Participant 
            / Thumb Impression 
Place : 
Date :  
PROFORMA 
 
Date :        Sample Id :  _____________ 
Name :    Age :   Sex :  Ht :   Wgt :  
Pre/Post Menopausal: 
Ethnicity :    Community :    Duration of 
Symptoms: 
Pregnancy      Lactation       Chest Trauma     
Other Autoimmune Diseases : ___________________   if any duration ________________ 
Associated diseases with duration : 
Renal Failure         PCOS       Hypertension     
Cardiac Failure         Tuberculosis      CNS Tumours     
Diabetes Mellitus     Untreated Primary Hypothyrodism     
Drug Intake: 
OC Pills        Antidepressants      Ergot Derivatives   
H2 Blockers         Antipsychotics       Chemotherapy      
Metoclopramide      Cannabis        Verapamil      
Alphamethyldopa    Isoniazid        Any other medications _______ 
Smoking :____________ Passive Smoking :__________ Alternative Medicine 
intake:______ 
Clinically : 
1. 2/↑ swollen joints : _________________________ 
2. Morning stiffness lasting more than 1hr for atleast 2 weeks : __________________ 
3. ↑RF / anti-cyclic citrullinated peptide :  
4. Symptoms of hypothyroidism. 
 
 
DAS 28(3) : 
Sample Collection  :  Date ________________ Time __________ 
Sample Analysis  :  Date ________________  
 
Investigations : 
 
 Hemoglobin  : 
 CRP   : 
 Sr.Prolactin  : 
Anti-CCP  : 
ESR   : 
TSH (if available) : 
JOINTS LEFT RIGHT 
 
Total Swollen Joints : 
 
Total Tender Joints : 
 
Swollen Tender Swollen Tender 
Shoulder     
Elbow     
Wrist     
MCP 
1     
2     
3     
4     DAS 28 (3)Score Activity 
5     < 3.2 Low 
PIP 1     3.2 to 5.1 Moderate 
2     > 5.1 High 
3      
4     
5     
Knee     
SUB 
TOTAL 
      
 
 
 
 
REVISED ACR CRITERIA – POINTS 
 
• 1 large joint  - 0  Negative RF/ Negative ACPA   - 0   
• 2-10 large joint  - 1   Low positive RF/ Low positive ACPA  - 2    
• 1-3 small joints with or without - 2  High positive RF / High positive ACPA - 3    
Large joint involvement 
• 4-10 small joints with or without – 3 Elevated ESR / Elevated CRP  - 1    
Large joint      
• >10 joints with involvement of  - 5  Duration of arthritis   - 1    
atleast 1 small joint       six weeks or longer 
 
    TOTAL POINTS :  ____________________ 
 
 
 
